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ABSTRACT

PROTECTION FROM AORTIC ANEURYSM BY BMAL1 DELETION FROM
SMOOTH MUSCLE CELLS

Abdominal aortic aneurysm (AAA) is a devastating condition that occurs primarily
among older people with high mortality when a rupture occurs. Currently there is no
proven pharmacological therapy for AAA due to poor understanding of the underlying
pathogenesis. The brain and muscle transcription factor ARNT-like (Bmal1), which is
known to regulate circadian rhythm, has been implicated in vascular pathologies
including atherosclerosis and vascular remodeling, but its role in AAA has not been
explored.
Vascular smooth muscle is a central player in aneurysm formation and
development because it is critical in all three aortic aneurysm hallmark processes
including (a) degradation of elastin and extracellular matrix protein, (b) loss of medium
layer smooth muscle cells, and (c) intense inflammatory cell infiltration.
Here we report that smooth muscle-selective deletion of brain and muscle Arntlike protein-1 (Bmal1) potently protected mice from AAA induced by mineralocorticoid
receptor (MR) agonist deoxycorticosterone acetate (DOCA) or Angiotensin II (ANG II) in
the presence of high salt. Bmal1 was upregulated by DOCA-salt in the aorta. Moreover,
deletion of Bmal1 in smooth muscle selectively upregulated tissue inhibitor of
metalloproteinase 4 (TIMP4) and also abolished DOCA-salt-induced elastin degradation
and matrix metalloproteinase (MMP) activation. Mechanistically, Bmal1, when bound to
TIMP4 promoter, suppressed the transcription of the promoter. Taken together, these
results reveal an important but previously unexplored role of smooth muscle Bmal1 in
DOCA plus salt-induced AAA. We suggest that TIMP4 constitutes a novel therapeutic
target for AAA treatment.

Keywords: Aortic Aneurysm, Bmal1, Vascular Smooth Muscle Cells, Matrix
Metalloproteinases, Tissue Inhibitor of Metalloproteinases.
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CHAPTER 1
Introduction

1.1. Aortic Aneurysm
1.1.1. Definition
Aortic Aneurysm (AA) is defined as the permanent and irreversible localized dilation of
the aorta1. An aortic dilation is considered aneurysmal with an increase of a minimum of
50% of the normal diameter2.
1.1.2. Type
1.1.2.1. Abdominal Aortic Aneurysm
Abdominal aortic aneurysm (AAA) is the most common form. Here the dilation occurs in
the infrarenal region of the aorta. It is most prevalent in men over the age of 65 and is
the 14th leading cause of death in the United States. Aortic aneurysm rupture accounts
for approximately 4500 deaths not including the 1400 deaths that occur due to surgical
repairs to prevent rupture. This chronic enlargement of the aorta is often asymptomatic
and frequently leads to rupture and death.
1.1.2.2 Thoracic Aortic Aneurysm
Another form for AA is thoracic aortic aneurysm (TAA); it is less common, occurring in
approximately 6-10 per every 100,000 people. The incidence of TAA formation is similar
in both genders and it occurs earlier in life than AAA. The majority of TAAs involve the
aortic root and/or the ascending aorta. Most patients with TAAs are asymptomatic. Just
like AAA, TAA is discovered during imaging screening. However, TAA progression is
rather slow; it grows at a rate of approximately 0.1cm/year, and an intervention is
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required only when the diameter reaches 5.0 cm to 5.5 cm3. The exceptions to this rule
are patients with a family history of TAA that later became an acute aortic dissection and
those with Loeys-Dietz syndrome. These patients have to undergo a surgical repair
when the aortic diameter reaches 4.2 cm4. TAA has a strong genetic component, and
five different TAAs have been identified. Like AAA, hallmarks of TAA involve changes in
the extracellular matrix (ECM).
1) Marfan Syndrome (MFS): was first described in 1896 and later found to be an
autosomal dominant genetic disorder in 19365. It is the most common genetic aortic
disease, occurring at approximately four to six people per every 100,000. It is best
known for its physical features which are pectus excavatum or sunken breastbone,
arachnodactyly or long and slender fingers and toes, tall stature, and lens ectopia. MFS
is caused by mutations in fibrillin-1(FBN1)6, a glycoprotein found in the ECM. It has been
shown to regulate TGF-β activity. A mutation in FBN1 prevents TGF-β regulation and
causing an increase in its activity7.
2) Loeys-Dietz syndrome (LDS) is the most recent syndrome discovered. It was
described in 2005 by Loeys et al8. Patients with LDS were initially misdiagnosed as
having either MFS or vascular Ehlers-Danlos (vEDS) syndrome because of the similarity
in phenotype with those two other syndromes. The most specific features to LDS are
hypertelorism and wide uvula. LDS is divided in two different types: 1) facial
dysmorphogenic type characterized by a cleft palate, micrognathia and craniosynostosis.
2) vascular EDS-like syndrome characterized by visceral rupture, easy bruising, wide
scars, joint laxity and translucent and velvety skin9. Other features have been described
in LDS with recent research which includes facial milia and an increase in eosinophilic
esophagitis as well as an increase inflammatory bowel disease10. LDS is caused by
mutations in the transforming growth factor receptor 1 and 2 (TGFR1 and TFGR2).
2

Among the two, the most frequent mutation is the one found in TGFR29. The types of
mutations do not lead to a specific type of LDS. Mutations in these two genes affect
TGFβ signaling and each mutation affects the pathway differently and has been shown
to also phosphorylate SMAD2 and subsequently activate the SMAD pathway11.
3) vascular Ehlers-Danlos syndrome (vEDS) was first described in 1901 and classified
as autosomal dominant in 194912. vEDS is less common than MFS occurring in one
individual in every 250,000. Patients with vEDS present the following clinical features:
thin skin with visible veins, easy bruising, thin pinched nose, thin lips, prominent ears,
hollow cheeks, and tightness of skin of the face. These patients have a short lifespan
with 50% risk of mortality at the age of 4813. vEDS is caused by mutations in type 3
procollagen (COL3A1) gene which is the major collagen in blood vessels. These
mutations cause weaknesses in the vasculature and the heart. In vEDS, the medium
and large arteries are susceptible to rupture; they can dissect without any dilation. The
aortic root is not affected. Because vEDS also affects other organs, in pregnancy the
enlarging uterus is susceptible to rupture in addition to other organs affected by an
increase in pressure. The risk of mortality among these pregnant women due to rupture
of the uterus is approximately 15%. Therefore, pregnant women with vEDS need to
undergo an elective caesarian section at 32 weeks of gestation13.
4) Turner syndrome was first described in the United States in 1938 and linked to
monosomy in 19595. Tuner syndrome is cause by a partial or a complete monosomy of
chromosome X (45 Xo). It is quite common occurring in one in every 2000-5000 women.
The physical features of Tuner syndrome are: short stature, webbed neck and
lymphedema. There are many diseases that are associated with individuals with Turner
syndrome including cardiovascular disease which is a main cause of mortality in these
patients. Only one percent of Turner conceptions survive. Those that survive are known
3

to develop aortic diseases as well as aortic aneurysm, elongation of the transverse arch,
and aortic coarctation14. They also develop abnormalities in the heart such as bicuspid
aortic valve and partial anomalous pulmonary venous return to the heart15.
5) Familial thoracic aneurysm and dissection (FTAAD): About 19% of individuals with
aortic dissection have had a first-degree family member affected with the same disease
that is not one of the genetic diseases mentioned above. It is believed that these
individuals have mutation in genes that have an autosomal dominant inheritance with
decreased penetrance. All these individuals are collectively placed in a group called
familial thoracic aortic aneurysms and dissection (FTAAD); they present a variety of
abnormalities, such that there is a large range of physical features among them16.
Presently, three different genes with mutations have been identified in the population.
First, mutations in the myosin heavy chain 11(MYH11) is expressed by smooth muscle
cells and is part of the smooth muscle cell contractile apparatus. Mutations in this gene
account for less than 2% of the FTAAD population. Second, mutations in smooth muscle
actin alpha2 (ACTA 2) is also a part of the contractile apparatus in smooth muscle cells.
Mutations of ACTA2 account for 14% of the FTAAD population17. Third are mutations in
SMAD3 gene which has been recently described among this population18. Mutations in
SMAD3 are thought to increase levels of CTGF, TGF-β1, and phosphorylated SMAD218.
Patients with this mutation have physical features similar to LDS; however, these
patients also have an increase in bone abnormalities. This syndrome is also called
aneurysm and osteoarthritis syndrome (AOS), and accounts for approximately 2 % of
FTAAD population.
For the purpose of this study, we had focused on AAA rather than TAA, since the former
is the most common of both types and it is primarily acquired, rather than genetic.
Therefore, we will discuss the risk factors, mechanisms and treatments of AAA.
4

1.1.3. Risk Factors
The risk factors associated with AAA are: age, sex, ethnicity, smoking and other
predisposing factors.
Age, sex and ethnicity: The risk of AAA increases dramatically after the age of 60.
Approximately 1% of men between the age of 55 and 65 have a clinically relevant
aneurysm. AAA is four to six times more common in men than in women, occurring
approximately 10 years later in women. However, once AAA develops in women, the
occurrence of AAA is more aggressive, and the aneurysm expands faster with a high
probability of rupturing with a small diameter19. Lederle et al. showed that Caucasians
were more prone to AAA than are African Americans 20.
Smoking: One of the major risk factor of AAA formation is smoking. In a study from
Lederle et al, they found that smoking accounted for 75% of all the AAA20. The number
of years of smoking was found to be directly proportional to the onset of AAA21.
Other predisposing factors: Hypertension has been shown to be a risk factor of AAA
formation and rupture. AAA has been shown to be common in patients with
atherosclerosis. It is also prevalent in patients with arteriosclerosis obliterans. Family
history is also a risk factor with 4-fold increase in AAA when a first-degree family
member is diagnosed with AAA.
1.1.4. Mechanisms
The mechanisms that lead to aortic aneurysm formation are not well understood.
However, there have been many hallmarks associated with aortic aneurysm. The
hallmarks of AAA are fragmentation of elastin in the aortic media and collagen
degradation, leukocytic infiltration and vascular smooth muscle cells depletion22,
5

23

.Elastin is a major component of the aortic wall with viscoelastic properties. It is most

abundant in the aortic media where it is associated with smooth muscle cells. Collagen,
another component of aortic wall, provides tensile strength to maintain structural
integrity. Smooth muscle cells are the major cell type in the aorta. Smooth muscle cells
and adventitial fibroblasts can synthesize all of the different components of the
extracellular matrix24. The lack of a definite definition of aortic aneurysm has led to
development of different animal models of aortic aneurysm. These models gave new
and better perceptive in the pathogenesis of aortic aneurysm. These models have
revealed that aortic aneurysm formation involves chronic inflammatory infiltration of
macrophages, neutrophils, mast cells, T and B lymphocytes. Different cytokines and
extracellular proteases have been shown to increase the inflammatory response and to
cause vascular smooth muscle cells apoptosis and extracellular matrix degradation.
Macrophages are the most common inflammatory cell in aortic aneurysm tissue. C-C
chemokine receptor type 2 (CCR2) interactions with chemokine (C-C motif) ligand1
(CCL2) mediates monocyte chemotaxis. MacTaggart et al investigated the role of CCR2
in aortic aneurysm formation using CCR2-/- mice. When those mice were treated with a
periaortic application of CaCl2 for 6 weeks, it was found those mice had an attenuation of
aortic aneurysm25. These findings were similar to a previous study from Ishibashi et al
using the ANGII model26. Myeloid differentiation factor 88 (MyD88) which also plays an
important role macrophage infiltration, has been found to play a role in aortic aneurysm
formation. Deficiency in MyD88 attenuates abdominal aortic aneurysm using the ANGII
model27. Neutrophils have also been found in human and mice aortic aneurysm.
Deletion of L-selectin, a molecule involved in neutrophil recruitment to inflammatory
sites28, decreased aortic diameter after elastase infusion29.
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Many different cytokines and chemokines have been studied in aortic aneurysm and
their roles have been established. Transforming growth factor (TGF-β) inhibits
inflammation, and stimulates collagen deposition. Systemic neutralization of TGF-β
activity was found to increase AngII-induced aortic aneurysm and increase vascular
smooth muscle cells death, elastin degradation and aortic rupture in C56BL/6 mice30.
Administration of cyclosporine A, an immunosuppressant that promotes tissue
accumulation and induces TGF-β, attenuates aortic aneurysm formation in an elastase
model in rats and CaCl2 model in mice, while administration of anti TGF-β antibody
abrogated the protective effects of cyclosporine A31.
Another critical cytokine that has been associated with aortic aneurysm is tumor necrosis
factor (TNF-α). TNF-α has been found to be increased in plasma of patients with AAA32.
TNF-α as well as other members of the TNF receptor superfamily have been found to be
increased in human aortic aneurysm tissues33-35. When TNF-α-/- mice underwent
periaortic application of CaCl2 for 6 weeks, those mice has shown complete protection
from aortic aneurysm. These results has shown that TNF-α is big contributor in the
formation of aortic aneurysm.
Several interleukins have been associated with aortic aneurysm including IL1-β, IL-6, IL17 and IL-23. They have been found to be increased in human aortic aneurysm tissues.
IL-6 is significantly increased in patients with AAA and TAA36. Using the elastase model
to induce aortic aneurysm, deletion of IL-17 or IL-23 in mice attenuates aortic diameter
and cytokine production37. Similarly, deletion of IL-1β in mice prevented aortic aneurysm
formation38.
Elastin degradation, an early event in AAA, causes dilation whereas collagen
degradation causes rupture. Elastin and collagen are degraded by endopeptidases that
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are secreted by smooth muscle cells and adventitial fibroblasts within the vascular wall
by infiltrated lymphocytes and monocytes. Matrix metalloproteinases (MMPs) are
endopetidases associated with AAA and are locally activated. Their actions are inhibited
by tissue inhibitor of matrix metalloproteinases (TIMPs) which also increased during
aneurysm formation, but TIMPs’ action is overwhelmed by a high increase of activated
MMPs by other MMPs or plasmin.
Another key event in the formation of an aneurysm is smooth muscle atrophy in the
medial layer of the aortic wall. Smooth muscle cells contribute to the maintenance of the
structural wall through production of various extracellular matrix proteins. They also play
a role in vascular remodeling by expressing proteinases and their inhibitors. In the
aneurysm pathology, SMC play a role in matrix synthesis, proteinase and inhibitor
elaboration, and inflammatory cell recruitment. The imbalance between matrix
metalloproteinases and their inhibitors is observed in aortic aneurysm, with the matrix
metalloproteinase overwhelming their inhibitors,

is attributed to either an increase in

matrix metalloproteinase production from smooth muscle cells or a decrease in tissue
inhibitor production from smooth muscle cells39. SMCs produce different proteinases in
response to different stimuli. Inflammation, shear stress, or injury to vessel walls lead to
an increase of MMP3, MMP7, MMP9, and MMP12 in vivo40, 41.
Studies have shown that smooth muscle cells play a role in matrix degradation in aortic
aneurysm42. SMCs from aortic aneurysm tissue express a high level of MMP2 compared
to non-aneurysmal aorta43. SMC constitutively express MMP2 and stimulation with
platelet-derived growth factor (PDGF) further increases its expression44. PDGF also
increases MMP12 expression in SMC45. The expression of MMP-9 and MMP-3 in SMC
are induced by IL-1β and TNFα46. These cytokines have been shown to be increased in
human aortic aneurysm tissue47. One of the final stages of AAA is medial degeneration.
8

The decrease in SMC in AAA has led researchers to hypothesize that the decrease in
SMC in the media is a key player in the imbalance between the metalloproteinases and
their inhibitors. Studies have shown that seeding of SMC prevents AAA formation. In a
study conducted in rats, seeding of syngeneic VSMC endoluminally prevented aortic
aneurysm increase after 8 weeks of aneurysmal aortic xenografts. The seeding also
prevented MMP1, 3, 7, 9 and 12 mRNA increases. TIMPs1, 2, 3 were significantly
increased when compare to their control48. A previous study from Losy et al. had also
shown that seeding of VSMC prevented aortic aneurysm expansion in rats49. These
studies suggest that SMC play a critical role in aortic aneurysm; therefore, there is a
need to better understand the role that smooth muscle cells play in aortic aneurysm
formation.
1.1.5. Animal Models
Animal models of aortic aneurysm are classified into three different groups: genetically
predisposed animal models, chemical models, and physical models.
1.1.5.1. Genetically predisposed animal models
The blotchy mouse, which has been found to develop spontaneous aneurysms, has a
mutation on the X chromosome resulting in a defect in cross-linking of collagen and
elastin. The defective cross-liking is a result of an abnormal copper metabolism. These
mice have abnormal connective tissue, skin color and neurological function50, they
develop saccular and fusiform aneurysms mostly in the thoracic aorta51. These findings
have led to the conclusion that copper is involved in aortic aneurysm formation.
However, there has not been any evidence from human patients with aortic aneurysm
that involved copper since copper levels remained unchanged in aortic aneurysm52,

53

.

Lysyl oxidase (LOX) is an enzyme involved in crosslinkage of elastin and collagen.
Deficiency of Lox in mice causes thoracic aortic aneurysm rupture from the perinatal
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period54. Apolipoprotein E (ApoE) and low-density lipoprotein (LDL) receptor knockout
mice develop abdominal aortic aneurysm after being fed with high fat diet55. The
Tsukuba hypertensive mouse, a transgenic mouse carrying a human gene for renin and
angiotensinogen56, dies from aortic aneurysm rupture after drinking water containing 1%
sodium chloride57.
1.1.5.2. Chemical models
Periarterial application of calcium chloride (CaCl2) solution to the infrarenal aorta causes
aortic aneurysm formation. This model was first developed using the rabbit common
carotid artery causing the local dilation of the artery. This was associated with loss of
endothelial cells, degradation of the elastin lamina, intimal hyperplasia, and inflammatory
infiltration. Subsequently, CaCl2 was applied to rabbit aorta. This model consists of
applying 0.5M of CaCl2 around the infra-renal aorta for approximately 15 minutes with
cotton gauze. This model has been demonstrated to induce medial damage and
vascular remodeling, collagen degradation, and an increase in MMP activity. CaCl2
induction does not lead to a spontaneous increase in aortic diameter. However, after 2
weeks, the aortic diameter increased by more than 64%, and increased more than
113% during the third week58. Disruption of elastin lamina and an increase in the
inflammatory response suggested that this model was clinically relevant since these
same features are found in human AAA. Using this model, the role of different MMPs in
aortic aneurysm formation has been better understood. Using genetically altered mice,
Longo et al. have shown that MMP2-/- and MMP9-/- mice did not develop AAA. MMP9-/mice developed aneurysm only after being infused with competent macrophages from
the wild type mice59. These findings showed that MMP2 and MMP9 are both required to
develop AAA. Longo et al. also determined the role of MMP12 using MMP12-/- mice;
they had demonstrated that MMP12 attenuates dilation of the aorta60. Since MMP
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activity is tightly regulated by TIMPs, the role of TIMPs has also been studied using this
model. TIMP2-/- mice were found to have a smaller aortic diameter than their
corresponding control after 6 weeks and had a lower level of MMP261, supporting
evidence that TIMP2 activates MMP2.
A modified model of CaCl2 was developed in order to accelerate AAA formation: calcium
phosphate (CaPO4). In this model, the infrarenal of the aorta is incubated with CaCl2 for
10 minutes followed by phosphate-buffered saline (PBS) for 5 minutes. This model
increased aortic diameter 7 weeks after treatment. CaPO4 treatment caused an increase
in apoptosis and inflammatory infiltration62.
The elastase-induced model is also an important model. The procedure involves the
insertion of a catheter in the infrarenal aorta through the iliac bifurcation. The aorta is
then clamped at the level of the renal vein and the catheter ligated. Type I porcine
pancreatic elastase in then introduced to the lumen and incubated for 5 minutes after
which the flow is restored. Elastase infusion resulted in immediate dilation of the aorta
and an aneurysm developed 2 to 5 days later. This outcome showed the involvement of
medial elastolytic activity in aneurysm formation making this model a very useful model.
This model has been used to investigate the role of hypertension, gender, and smoking
in aortic aneurysm formation. To understand the role of hypertension in aortic aneurysm
formation, aortic aneurysm was induced in normotensive Wistar-Kyoto rats (WKY) and
hypertensive Wistar Kyoto rats (WKHT) using the elastase infusion model. Around day
7, the aortic diameter was significantly larger within the hypertensive group than the
normotensive group. Fourteen days after infusion, the aortic diameter increased even
further in hypertensive rats. Although the normotensive rats had an increase in aortic
diameter of over 100%, the genetically hypertensive rats had an increase in aortic
diameter of over 200%63. These results suggested that hypertension contributes to the
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expansion of aortic aneurysm. Gender was studied as a risk factor using the elastaseinfusion model. It has been demonstrated that when male rats are treated with
exogenous estrogen, their aortic diameter was smaller than non-treated male rats. This
decrease in aortic diameter was also seen in orchidectomized male rats. Hormone
replacement in male rats that were surgically castrated showed an increase in aortic
diameter while there was a decrease in aortic diameter in oophorectomized females.
This decrease in aortic diameter was associated with a decrease in macrophage
infiltration64. These data suggest that gonadal hormones regulate aortic aneurysm by
altering macrophage infiltration. Smoking being a major risk factor of aortic aneurysm
formation was investigated when C57BL/6 mice were exposed to cigarette smoke two
weeks prior to elastase infusion and continuously until the aorta was harvested. Mice
that were exposed to both cigarette smoke and elastase developed a larger aortic
aneurysm compare to those that only were elastase infused. The increase in diameter in
mice exposed to both was 60% greater than those that had elastase infusion65. The
results confirmed the risks of cigarette smoking in aortic aneurysm development. This
model was also used to look at the role of TIMPs in aortic aneurysm formation. When
TIMP1-/- and their control underwent elastase infusion to induce aortic aneurysm,
TIMP1-/- mice developed a larger aortic aneurysm compare to the control 14 days
later66.
Systemic angiotensin II infusion is a model described by Manning et al. and shares the
same characteristics as human aortic aneurysm. In this model, AngII in an osmotic minipump is implanted subcutaneously into LDL receptor-/- mice or ApoE-/- mice at a
dosage of 1000ng/kg/min for 28 days. This model results in accelerated atherosclerosis
and abdominal aortic aneurysm in the suprarenal aorta67. AngII induced aortic aneurysm
results in medial degeneration and remodeling, inflammation, and thrombosis. Data have
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shown an increase in inflammation and an increase in MMPs gene expression68. These
characteristics are also seen in human aortic aneurysm, making this model a good
model to study aneurysm. AngII infusion has a modest increase in blood pressure; this
increase in blood pressure was shown to be independent of aortic aneurysm formation.
When hydralazine was given to lower blood pressure in AngII infused ApoE -/- mice,
blood pressure decreased; however, aortic aneurysm formation did not change69. The
incidence of aortic aneurysm in these mice only decreased with pretreatment with 17βestradiol70. The renin-angiotensin system has been studied to understand its role in this
model. When losartan, an AT1 receptor antagonist, was given in conjunction with AngII
to ApoE-/- mice, aortic aneurysm formation was completely inhibited71. Candesarten,
another AT1 receptor antagonist and Lisinopril, an ACE inhibitor, attenuated aortic
aneurysm expansion72. When given an AT2 receptor antagonist PD123319, the
incidence of aortic aneurysm increased as well as the severity71. However,
spironolactone, an aldosterone receptor antagonist, there was no effect on aortic
aneurysm formation73. Several drugs have been shown to attenuate aortic aneurysm
formation and reduce incidence in this model: Doxycycline74, Vitamin E75, simvastatin76
and rosiglitazone77.
A mineralocorticoid agonist plus salt induces aortic aneurysm in mice. This model was
first developed as a hypertension model and was later found to develop AAA in older
mice (8 to 10 months). Subcutaneous implant of a 50 mg Deoxycorticosterone acetate
(DOCA) pellet or an osmotic pump containing 200ng/kg/min of aldosterone in
conjunction with water containing 0.9% NaCl and 0.2% KCl for 21 days with the DOCA
pellet and 28 days with the osmotic pump leads to dilation of the aorta in the suprarenal
aorta. This model requires high salt intake. Liu et al. had demonstrated that in the
absence of high salt, mice did not develop any aneurysm. This model was shown to be
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clinically relevant and to be age-dependent. The incidence and severity of AAA were
significantly lower in young (10 weeks old) mice compare to older (10 months old) mice.
This model shared the same characteristic as human aortic aneurysm: elastin and
collagen degradation, MMP upregulation, vascular smooth muscle cells degeneration
and inflammatory cells infiltration.
1.1.5.3. Physical Models
Different physical techniques have been used in order to create aortic aneurysm in
animals. However, these techniques do not completely mimic human aortic aneurysm.
Therefore they are used to develop new interventions for abdominal aortic aneurysm
formation. These models have led to the development of techniques such as stent grafts
and the improvement of the endovascular repair78.
The crude method induces aortic aneurysm by physically damaging the vessel by either
intramural injections of chemicals such as acetrizoate or using cryogenic probes, carbon
dioxide lasers or resecting the media and adventitia of the aorta79-82. The aneurysms
formed from these methods are usually saccular aneurysm or pseudoaneurysm. They
are unpredictable in size, growth rate and rupture risk.
The synthetic method requires replacing a segment of the aorta with interposition grafts
made of synthetic or autologous materials. The aneurysms from this method are more
consistent in shape and size83.
The anterior patch model: in this model an elliptical patch of synthetic materials is placed
after a longitudinal incision to the aorta to close the incision. This is one of the successful
models of physical model of aortic aneurysm. A study from dogs that underwent the
procedure had shown an anterior patch in the infrarenal of the aorta by suturing full
thickness of the jejunal patches to the interior of the longitudinal aortic incision,
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developed aortic aneurysm. This study was performed in order to determine the efficacy
of the endovascular aortic repair84. This model was also used to determine the efficacy
of a specific stent graft design. In this study a fusiform aortic aneurysm was formed
using an iliac vein patch. This technique was shown to be realistic. Twenty-three dogs
were used following this technique after developing aneurysm they were treated with
Dacron stent grafts and followed up after 6 to 12 months. At 12 months, no leaks or flow
to the sac of the aneurysm were detected and there was no further enlargement on the
aneurysm85.
1.1.6. Treatment
Aortic aneurysms are often discovered after an X-ray, during an ultrasound or
echocardiogram. Thereafter, ultrasounds are required to determine the size and the
growth rate of the aneurysm. For small aneurysm, an ultrasound is required once every
2 years, while larger aneurysms are observed every 6 to 12 months. A computed
tomography (CT) or magnetic resonance angiogram (MRA) may be required for more
detailed information, such as determining the position of the aneurysm in relation to the
renal arteries or other organs. An angiogram is more useful to determine the size of the
aneurysm, whether there is an aortic dissection or a blood clot. The importance of these
screening tests is to estimate the risk that an aneurysm has for rupture and to evaluate
the risk of rupture to the risk of surgery. The risk of mortality is about 80% for patients
with a ruptured aorta by the time they reach the hospital. Those who undergo surgery
have a perioperative mortality of approximately 50%. An aortic aneurysm is considered
for surgery when the diameter reaches 5.5 cm. The surgery is either an open or
endovascular repair (EVAR). An EVAR consists of placing an expandable stent graft in
the aorta through the femoral artery. This technique led to a decrease in open surgery
and improved patients’ survival. Therefore, it was found to be more successful than open
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surgery. Candidates suitable for EVAR have a reduced morbidity and mortality. Patients
with small aneurysms (less than 5.5 cm) are not at high risk of rupture. These patients
are required to undergo pharmacotherapy to reduce the growth rate. Beta-blockers have
been used in patients with hypertension and angina, they have been shown to
significantly reduce the rate at which aneurysms grow86. Those that undergo antibiotic
therapy to manage AAA need to have evidence of chronic inflammation in AAA. They
also have to show inhibition of proteases and inflammation by antibiotics. These patients
are also recommended to stop smoking.
To date, the only therapy for AAA is through mechanical surgical repair.
Therefore, a thorough understanding of the molecular mechanism of aortic aneurysm is
a pressing matter.
1.2. Matrix Metalloproteinases

Matrix metalloproteinases (MMPs) are members of a large family of proteases known as
metzincin superfamily. They are also known as matrixins. They are calcium-dependent
zinc-containing endopeptitases. Other members belonging to metzincin superfamily are
serralysins, astacins, adamalysins or desintegrin metalloproteinases (ADAMS) and
reprolysins87. Taken together, MMPs are capable of degrading all components of the
extracellular matrix (ECM) and the basement membrane. They play an important role in
tissue remodeling, angiogenesis, bone development, wound healing, and uterine
biology. They have been shown to play a role in regulating the release and the activation
of cytokines and chemokines, growth factors and antibiotic peptides and other bioactive
molecules88-90. MMPs also play a role in different diseases: vascular diseases such as
hypertension, atherosclerosis, aortic aneurysm and varicose veins, cancer and different
types of inflammatory pathologies.
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1.2.1. Classification
To date, there are 28 MMPs classified among which 25 different MMPs have been
identified in vertebrates, 24 of which are found in humans including two identical genes
encoding for MMP23 called MMP23A and MMP23B91. MMPs are synthesized as preproenzymes and secreted as pro-enzymes. They can be secreted form the cell or anchored
to the plasma membrane which limits the catalytic activity to the extracellular space or to
the cell surface. They consist of a pro-peptide domain that is uniquely conserved and
contains a cysteine residue within the sequence that interacts with the catalytic zinc in
the active site to maintain the latency of the enzyme. However, MMP23 lacks this linker
peptide, but possesses proprotein at the C-terminal end of the propeptide, which is
activated intracellularly by furin. MMPs are commonly classified based on their structure,
their substrate and subcellular localization and are divided as followed: collagenases,
stromelysins, matrilysins, gelatinases and furin- activatable MMPs.
Because of their difference in sequence and substrate specificity MMP12, MMP19,
MMP20 and MMP27 are not classified. MMP12 also known as macrophage
metalloelastase is mainly expressed in macrophages and it is the potent elastolytic
enzyme92. In humans, MMP19 is expressed in many different tissues and has shown to
be a very potent degradative enzyme. It can also degrade gelatin, aggrecan and type IV
collagen93. First isolated from a porcine enamel organ, MMP20 also known as
enamelysin is secreted by odontoblast of the dental papilla and ameloblast94, 95. Besides
the fact that MMP20 is highly expressed in B-lymphocytes, and that it can degrade
gelatin and casein, little information is known about human MMP27. However, it was first
identified from chicken embyo fibroblasts96.
MMP1, MMP8, and MMP13 degrade collagen. They are also called collagenase 1,2 and
3 respectively. They are so called because of their ability to first unwind triple helical
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collagen and then to cleave fibrillar collagen type I, II and III into characteristic 3/4 and
1/4 fragments. Their hemopexin domain is essential for the degradation of the native
collagen. Once this domain is removed, the MMPs are unable to carry out their catalytic
abilities97.
Matrilysins have 2 members MMP7 and MMP26 also known as matrilysins1 and
matrilysins2 respectively. They lack the carboxy-terminal hemopexin domain. The have
been involved in the degradation of ECM like laminin, entactin and type IV collagen.
MMP7 has been shown to cleave cell surface molecules such as Fas-ligand, syndecan 1
and E-cadherin to generate soluble forms. MMP26 is expressed in breast cancer cells98
and is an activator of pro-MMP9 under pathological conditions99.
Stromelysins have 3 members: MMP3, MMP10 and MMP11 also known as stromelysins
1,2 and 3 respectively. They have a structural design similar to the collagenases; they
can degrade many different ECM components but cannot cleave native collagen. MMP3
and MMP10 have similar structure and possess the same substrate specificity. They are
secreted as inactive proMMP, while MMP11 is distant in its structure and has very weak
activity toward ECM. It is secreted as an active enzyme since it is activated
intracellularly. MMP3 and MMP10 have the ability to remove the propeptide domain of
the three procollagenases as well as proMMP9 and activate them.
Gelatinases have two members: MMP2 or gelatinase A and MMP9 or gelatinase B. They
play an important role in the remodeling of collagenous ECM. They possess three
repeats of type II fibronectin located inside the catalytic domain, allowing them to
degrade denatured collagens and gelatins. They degrade different components of the
ECM such as collagen type I, IV, V, VII, IX, X, elastin, fibronectin, aggrecan, vitronectin
and laminin100. They are also capable of degrading non-ECM molecules such as pro-
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TNFα101, TGFβ102 and MCP3103. They are expressed in fibroblasts, keratinocytes,
endothelial cells, chondrocytes and monocytes.

Both MMP2 and MMP9 have been

shown to play a role in many pathological diseases including inflammation, cancer,
vascular disease such as artherosclerosis and aortic aneurysm, cancer and bone
diseases.
Furin-activable MMPs have two different subgroups: secreted MMPs and membranetype MMPs. They are called furin-activatable because they possess a prohormone
convertase cleavage site or furin recognition site between the propeptide and the
catalytic domain.
Secreted MMPs has two members MMP21 and MMP28. In general, MMPs are secreted
in the inactive form and the uniqueness of these enzymes is that they are activated
intracellularly by a furin-like protease and secreted as active enzymes. MMP21is
expressed in different tissues such as kidney, intestine and skin during embryonic
development. MMP28 has not been well documented and its role is not clearly defined. It
has been shown to play a role in various diseases such as cancer, multiple sclerosis and
certain disease of the central nervous system.
Membrane-type MMPs are classified into two groups: type I transmembrane MT-MMPs
and glycosylphosphatidylinositol (GPI) MT-MMPs. These MMPs are located on the cell
surface. Type I transmembrane MT-MMP are anchored to the plasma membrane
through a transmembrane domain and the GPI MT-MMP through a GPI anchor. Type I
transmembrane MT-MMPs members include MMP-14 or MT1-MMP, MMP-15 or MT2MMP, MMP16 or MT3-MMP and MMP24 or MT5-MMP. These type I transmembrane
MT-MMP share the same structural domain. Synthesized a pre-pro enzymes, processing
of the signal and prodomain occurs before they are secreted into the cell surface. GPI
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MT-MMP include MMP17 or MT4-MMP and MMP25 or MT6-MMP; they also share the
same structural domain. The GPI-anchoring peptide is a hydrophobic amino acid stretch
at the C-terminus. When GPI-MMPs are secreted, they are secreted as pre-proenzyme
anchoring this hydrophobic sequence. While MMP17 has a low enzymatic activity to
cleave ECM components, MMP25 has been shown to cleave a broader range of ECM
components; this includes gelatin, collagen IV, fibronectin, fibrin and proteoglycans.
MMP25 is expressed in leukocytes, lung and spleen and MMP17 in brain, colon, ovary,
testis and leukocytes.
1.2.2. Regulation of MMP enzymatic activity
MMPs are considered important regulators for “tissue homeostasis and immunity in the
network of multidirectional communication within tissues and cells”104 because they can
degrade a broad spectrum of substrate. Therefore, their activities are tightly regulated.
MMP catalytic activity is tightly controlled at four different levels: 1) at the transcriptional
and post translational level; 2) their compartmentalization; 3) MMP activation and 4) their
inhibition by endogenous inhibitors i.e. tissue inhibitors of matrix metalloproteinases
(TIMPs) and other non-specific proteinase inhibitors such as α2-macroglobulin.
MMP gene expression is primarily regulated at the transcriptional level resulting in a low
level of mRNA expression under normal physiological conditions. It has been recently
reported that MMP post transcriptional stability is tightly regulated by cytokines, nitric
oxide, or micro-RNA.

A common cis-element within the promoter region is shared

amongst many of the MMP family members; supporting evidence that MMPs are coexpressed or co-repressed by various stimuli, including inflammatory cytokines, growth
factors, glucocorticoids, or retinoids105. The most surprising finding is the clear distinction
in promoters of functionally related MMPs such as MMP2 and MMP9 or gelatinases and
MMP1 and MMP8 or collagenases. Based on the composition of the cis-element, MMP
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promoters are grouped into three different categories. The first category which includes
most MMP promoters contains a TATA box and an AP-1 binding site; most of which
have a PEA3-binding site adjacent to the AP-1 binding site. This PEA3 binding site is
primarily responsible for controlling MMP transcription by cytokines and growth
factors106. The second category is a category of MMP promoters that have a TATA box
but do not have an AP1-binding site which allows for a more simple and distinct
regulation of the promoter. The Third category is a category of MMP promoters that do
not contain a TATA resulting with transcription starting at multiple sites. These MMPs
include MMP2, MMP14, and MMP28107. Other factors that influence the transcriptional
control of MMPs are epigenetic mechanisms such as DNA methylation and/or chromatin
remodeling with histone acetylation. Hypermethylation represses MMP Transcription108
while hypomethylation is regulatory for MMP expression109,
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. In conclusion, different

factors are required for MMP transcription:1) recruitment and cooperation of transcription
factors, 2) chromatin remodeling factors, 3) histone-modifying enzymes and 4) basal
transcription machinery to a promoter111.
Recent studies show that posttranscriptional mechanisms are also involved in the control
of MMP expression in response to certain cues. Overall et al. showed that in human
gingival fibroblasts and prostate cancer, TGFβ extends the half-life of MMP2 and MMP9,
and increases their levels112. Post-transcriptional mechanisms regulate MMP mRNA
stability and require elements with specific sequences: multiple AU-rich elements (ARE)
mostly located in the 3’ untranslated regions (UTRs). The stability is facilitated by transacting RNA-binding proteins that interact with the ARE. Increase binding of HU protein
family factors to ARE element enhances mRNA stability while binding of destabilizing
proteins promotes mRNA degradation. MMP activity is compartmentalized where and
how MMP is released and held in the pericellular environment is also an important
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process especially for the regulation of MMP proteolysis. Secreted MMPs are often
associated with the cell membrane which leads to substrate specificity in the pericellular
space. MMP9 has been shown to be recruited and bind to CD44102.
MMPs are synthesized as inactive enzymes in the pro-form or zymogens. Their
activation consists of removing the pro-domain harboring a cysteine rich motif or
cysteine switch. The conformational change in the pro-domain is what determines the
activation of the pro-MMPs. This conformational change exposes the cysteine residue
which in turn will allow the water to interact with the zinc ion in the active site. There are
three different mechanisms known to initiate this event: 1) direct cleavage of another
endoproteinase to remove the pro-domain; 2) allosteric reconformation of the prodomain and 3) modification of the pro-domain through chemical reaction such as with
reactive oxygen species or nonphysiological reagents. Allosteric reconformation of the
pro-domain and the chemical modification of the pro-domain can allow the enzyme to
remove its own pro-domain by autoproteolysis113. Activation of pro-MMP is believed to
be a process that involves multiple steps and take place in the pericellular membrane.
The first step is the conformational change that causes the exposure of the cysteineswitch and its subsequent disruption by interaction with the zinc ion. Partially activated
MMP intermediates or other active MMPs remove the pro-domain through intra or
intermolecular processing114.

Pro-MMP2 activation has been the most documented

activation, and MT1-MMP or MMP14 plays a very important role. Pro-MMP2 forms a
complex with TIMP2; this complex interacts with the catalytic domain of MT1-MMP via
the N-terminal domain of TIMP2 and forms a cell membrane-associated ternary
complex. The activation of pro-MMP2 is triggered by a second MT1-MMP which would
cleave the pro-domain115. The activation is completed by autolytic cleavage by MMP2116.
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In vitro studies have shown that pro-MMP can be activated by thiol-modifying chemical
agents such as mercurial compounds, SDS, oxidized glutathione and reactive oxygen
species. These agents cause activation of several pro-MMPs. Reactive oxygen species
activate pro-MMP via interaction of oxidized thiol and the zinc ion in pro-enzyme and
autocatalytic cleavage117. Reactive oxygen species have also been shown to inactivate
MMPs during increased inflammation118. Whether ROS can directly activate or inactivate
MMPs in vivo has not been established.
Pro-MMPs can also be activated via the intrinsic allostery of MMP molecule. Fujita et al.
have demonstrated that pro-MMP7 can be activated pericellularly by tetraspanin CD151
which is overexpressed in osteoarthritic articular cartilage. This increase in CD151 leads
to an excess of MMP7 activity therefore causing cartilage destruction119. Later on,
Geurts et al demonstrated that pro-MMP9 activation with hemin or beta-hematin, the
core constituent of hemozoin, resulted in autocatalysis of the prodomain mediated by
allosteric interaction with the hemopexin domain120.
In vitro studies have shown that pro-MMPs can be activated by a single member of
either serine proteinases or other MMPs such as MMP3 and MMP14. However, in vivo
studies show that activation of pro-MMPs can be trigerred by more than one mechanism
and can involve more than one participant. This has been supported using animal
models. MMP3 has been shown to activate pro-MMP9 in vitro. It was suggested that
MMP3 may play a key role in pro-MMPs activation121. However, complete deletion of
MMP3 in mice does not attenuate MMP2 or MMP9 activation after perivascular electric
injury either in the carotid artery or the femoral artery122. Furthermore, it is well
established that MT1-MMP plays a key role in pro-MMP2 activation. MT1-MMP deletion
does not prevent pro-MMP2 activation in fibroblasts from MT1-MMP knockout mice after
treatment with ascorbic acid123. Other supportive studies are: one from Lijnen at al who
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have shown that in vivo plasminogen does not necessarily activate pro-MMP2 and proMMP9 by using plasminogen deficient mice124 and another from Tchougounova et al
who showed that chymase deficiency partially prevented pro-MMP2 and pro-MMP9
activation125. These data strongly suggest that the mechanisms by which pro-MMPs are
activated in vivo are still not clear.
It has been well established in vivo that maintaining a balance between active MMPs
and their inhibitors is critical in order to avoid diseases caused by uncontrolled ECM
turnover, inflammation, dysregulated cell growth, and migration. There are two major
inhibitors: tissue inhibitors of metalloproteinases (TIMPs) and α2-macroglobulin. Human
α2-macroglobulin is a broad spectrum inhibitor. It inhibits almost all endopeptidase in the
body fluids and blood by engulfing the entire enzyme; this complex is then cleared by
LDL receptor related protein-1 mediated endocytosis126. In tissue there are four inhibitors
known as TIMPs. Each TIMPs inhibit MMPs with a 1:1 molar ratio. TIMPs are broad
spectrum inhibitors of MMPs, but they differ in their specificity. Data have shown that
TIMP2, TIMP3 or TIMP4 can interact with pro-MMP2 and TIMP1 or TIMP3 with proMMP9127. The role that TIMP2 plays when interacting with pro-MMP2 has been well
established. However, the role of other TIMPs interaction is not known. Of all the TIMPs,
only TIMP3 have shown to be the most relevant in vivo. Since TIMP3 deficient mice
were shown to develop pulmonary alveolar enlargement and enhanced apoptosis in
mammary gland duct epithelial cells with age128, while TIMP1 and TIMP2 deficient mice
have not been seen with any abnormalities. TIMP4, which is the newest recognized
addition to the TIMP family, has not been well studied. TIMP4 knockout mice were
recently developed and thus far have shown to be normal
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. Other molecules have

been shown to inhibit some MMPs. Procollagen C proteinase enhancer has been shown
to be an inhibitor of MMP2130. MMP2, MMP9 and MMP14 activities can also be inhibited
24

by

the

glycosylphosphatidylinositol

(GPI)

anchored

angiogenesis

suppressor

glycoprotein RECK131.
1.2.3. Matrix Metalloproteinases and AAA
Many MMPs have been implicated in human aortic aneurysms. MMP9 is the most
studied. MMP9 is the most abundant elastolytic proteinase produced by human tissues
in vitro and is highly expressed in macrophages infiltrated within the aneurysm tissue132.
Data suggest that the size of the developing aneurysm is determined by the type of
MMP within the aortic media133. Smaller aneurysms have higher level of MMP2 whereas
medium and larger sized aorta and ruptured aneurysm have a higher level of MMP9132,
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. The roles of MMP2 and MMP9 in aortic aneurysm have been well established. Longo

et al. have reported a relationship between these two gelatinases in aortic aneurysm
formation. They found that when MMP2-/- mice and MMP9-/- mice were treated with
CaCl2, none of these mice had developed AAA. However, reconstitution of MMP9 by
intravenous infusion of wild type mice macrophages into both mice resulted in AAA
formation in MMP9-/- mice but not in MMP2-/- mice59. These data suggest that both
MMP2 and MMP9 are required for AAA formation. Other MMPs have been implicated in
AAA formation; these include MMP1, MMP3, MMP12, MMP13 and MT1-MMP. MMP1
and MMP3 have been shown to be elevated in plasma of patients with AAA135. MMP12,
MMP13 and MT1-MMP are increase in AAA tissue136-138, with MMP13 been highly
expressed in medial smooth muscle cells136. Cigarette smoking, a major risk factor in
aortic aneurysm, increases MMP1 in rabbits’ aortic tissue139. While MMP1 has been
shown to be increase in sites of in human AAA tissue where collagen generation could
be important140, other data have shown that there is no correlation between MMP1 level
in the plasma and the size of the AAA141. Immunohistology demonstrated that MMP12 is
more localized at the elastin fiber fragments142. Deficiency in MMP12 in mice was shown

25

to attenuate AAA growth after periaortic application of CaCl2, but does not affect MMP2
and MMP9 expression138. MMP3 deficient mice were shown to have an attenuated aortic
diameter, and the expression of MMP3 in the wildtype mice was co-localized with
macrophage infiltrates143.
Due to the high implication of MMPs in aortic aneurysm formation, many drugs that
target MMPs and inhibit their activities have been studied as potential treatment for small
aneurysm to prevent AAA expansion. Non-steroidal anti-inflammatory drugs (NSAID)
have been widely used for their ability to suppress MMP expression and potentially
reduce aortic aneurysm dilation. In a study conducted in rats, indomethacin treated rats
had a decrease in MMP9 production and an attenuated aortic diameter after elastase
infusion144. Marimastat, a synthetic molecule designed to mimic MMPs substrates,
prevented MMP2 activation and elastin degradation in aortic organ culture145.
Investigation of CGS27023A, a broad-spectrum MMP inhibitor, showed a reduction in
aortic medial elastin degeneration and ectasia grade, suggesting that MMP inhibition can
prevent or slow an aortic aneurysm progression146. Many studies have demonstrated
that doxycycline treatment inhibits MMP synthesis; therefore, preventing elastin
degradation and aortic aneurysm expansion. Doxycycline has the ability to bind to any
MMP at the active zinc site causing a conformational change and loss of enzymatic
activity147. Oral administration of doxycycline in AngII treated mice reduced the incidence
of AAA as well as the severity of the aneurysm74. In a double-blind, randomized,
placebo-controlled study, patients with small AAA that received doxycycline daily for 3
months and were then monitored for 18 months had a decrease in aneurysm
expansion148. However, this study was criticized at different levels. One point was the
size of the diameter in the doxycycline group vs the placebo group. Within the
doxycycline group, average diameter was 3.1cm which according to Baxter is
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considered dilated but not aneurysmal, and the placebo group had a much larger
diameter (3.5cm). The most significant point was that during the whole 18 months period
there was no significant difference between the placebo group and the doxycycline
group. Significance was only seen when both group were subdivided into different group
6-12 month and 12-18 month149. Doxycycline had shown to be beneficiary in animal
studies, but in human studies, different trials provided conflicting evidence150. Thus, the
effectiveness of Doxycycline as a MMP inhibitor to treat small aneurysm is yet to be
determined.
1.3. Tissue Inhibitors of Metalloproteinases (TIMPs):
1.3.1. Classification and regulation
Tissue inhibitors of metalloproteinases (TIMPs) are endogenous inhibitors of the matrix
metalloproteinases and are consequently important regulators of ECM turnover, tissue
remodeling and cellular behavior151. There are four human paralogous genes that
encodes for TIMPs1-4. The first TIMP was identifying in the 1970s and described as a
small collagenase inhibitor because of its ability to inhibit collagenase produced in the
media cultured human skin fibroblast152, human serum153, bovine cartilage and aorta154.
It was then called “tissue inhibitor of metalloproteinases” for its ability to not only inhibit
collagenases, but gelatinases and proteoglycanase as well155. Subsequently, other
TIMPs were also discovered with the most recent being TIMP4. All four TIMPs inhibit all
identified MMPs; but, their affinity varies with different MMPs. TIMP3 has a broader
inhibition

spectrum,

and

it

can

inhibit

some

members

of

the

disintegrin

metalloproteinases, ADAM and ADAMTs families. TIMPs also have other functions
independent of inhibition of metalloproteinase. They can regulate cell proliferation,
angiogenesis and plasticity. The structure, activity and biological function of all four
TIMPs has been investigated thoroughly.

27

All four TIMPs are similar in structure; they are about 40% identical in sequence. TIMP2
and TIMP4 share the most similarity; they are about 50% identical in sequence, and
TIMP1 shares around 41% of its sequence with other TIMPs156. The genes for TIMPs1,
3, and 4 lay within an intron of the synapsin genes. Synapsins are genes that encode for
neuro-specific phosphoproteins that coat the cytoplasmic surfaces of synaptic
vesicles157. TIMP2 is the host for the gene DDC8 (differential display clone 8), a gene
that is highly expressed in the testis during spermatogenesis158. The four TIMPs have
two distinct domains, an N-terminus domain of about 125 amino acid residue and a Cterminus with 65 amino acid residues. There are three disulfide bonds that stabilize the
conformation of each domain159. The N-terminal domain has the ability to fold and
function independently. N-TIMPs, which have the recombinant form of the N-terminal
domain, are more stable in structure and are fully active inhibitors of MMPs and
ADAMS160,

161

.

Therefore, they are used to investigate different TIMPs properties.

Although the four TIMPs share similarities in their structures, they do have differences in
expression pattern. TIMPs 1, 3 and 4 are inducible and tissue specific while TIMP2 is
more constitutive and ubiquitous. TIMP1 is mainly expressed in the reproductive system,
TIMP3 is more seen in the heart, kidney, and thymus and TIMP4 is highly expressed in
the cardiovascular system, as well as, kidney pancreas, colon, testes, brain and adipose
tissue162.
The four TIMPs are broad-spectrum inhibitors of all MMPs identified to date. However,
their affinity and specificity differ among them. TIMP1 is the most restrictive TIMP in its
ability to inhibit MMPs. TIMP1 inhibits MMP1, MMP3, MMP7 and MMP9; it has very low
affinity for MMP14, MMP16, MMP19, MMP24 and the membrane-type MMPs. TIMP2 is
the only TIMP that interacts on the cell surface with MT1-MMP and pro-MMP2, and is
required for the activation of pro-MMP2115. TIMP2 can also inhibit MMP2. TIMP2 thus
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acts as both an MMP inhibitor and an activator. TIMP3 has a bigger spectrum of
inhibition. It can also inhibit members of the ADAM and ADAMTs families while the
activity of other TIMPs in this regard are limited161, 163.
ADAMs (disintegrin and metalloproteinase motif) vary from MMPs in their domain
structures and are very different in their catalytic domain sequences. They contain a
disintegrin, cysteine-rich, EGF-like transmembrane domains C-terminal in their catalytic
site

and

they

are

membrane-bound

enzyme164.

ADAMTs

(disintegrin

and

metalloproteinase with thrombospondin motifs), are secreted proteins. They possess the
disintegrin domain and different numbers of thrombospondin type1 motifs and other
domain in their C-terminal domain165. TIMP1 and TIMP3 inhibit ADAM10163 and TIMP2
inhibits ADAM12166. TIMP1 and N-TIMP4 inhibit ADAM 17167, and TIMP4 inhitbits
ADAM28168. TIMP3 also inhibit ADAM12, 17, 28, and 33 as well as ADAMTs 1,2,4 and
5. TIMPs usually inhibit MMPs and ADAMs using the N-terminal domain. However,
TIMP1 and TIMP3 do not use their N-terminal domain to inhibit ADAM10169.
1.3.2. TIMPs and AAA
Disruption of the balance between MMPs and TIMPs may result in diseases associated
with uncontrolled turnover of matrix, such as aortic aneurysm. The functions of TIMPs
have been investigated to understand their role in AAA formation. TIMP1 mRNA has
been found to be increased in human AAA tissues170 and in murine model of AAA171.
TIMP1-/- mice after a periaortic treatment of CaCl2 were found to have an increase in
aortic diameter compare to control66. Local overexpression of TIMP1 in the rats’ aortas
prevented elastin degeneration and therefore prevented aneurysm formation172. Three
different TIMP1 single nucleotide polymorphisms (SNP) have identified in male
Caucasian patients with AAA173. TIMP2, a cofactor in MMP2 activation, have been
shown to prevent aortic aneurysm increase in genetically deleted TIMP2 mice model
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with CaCl261. On the hand, overexpression of TIMP2 by recombinant adenovirus in rat
aorta

also

prevented

an

increase

in

aortic

diameter

by

preventing

elastin

degeneration174. These data are consistent with the complex function of TIMP2 in MMP2
activation. An increase in TIMP2 has been shown to activate MMP2 activity; however an
overexpression of TIMP2 inhibits MMP2 activity175. TIMP3-/- mice, when treated with
ANGII, had an increase in aortic aneurysm formation and rupture176. While a role of
TIMP1/2/3 in aortic aneurysm has been reported172, 174, 176, whether TIMP4 is involved in
aortic aneurysm is unknown. Several lines of evidence implicate a role for TIMP4 in
AAA: 1) it non-selectively inhibits MMP activity; 2) TIMP4 is down-regulated in
intracranial aneurysms177; 3) a Promoter SNP in TIMP4 gene has been associated with
Kawasaki disease, a systematic vasculitis178 and 4) TIMP4 is an inducible gene179.
1.4. Molecular clock Bmal1
1.4.1. Regulation
Brain and muscle ARNT-like (Bmal1; also known as MOP3 in human or Arnt3 in mouse),
is a member of the basic helic-loop-helix period-ARNT period-ARNT-single minded
(bHLH-PAS) transcription factor family. It is an obligatory core clock gene and is
essential for normal circadian rhythmicity in physiology and behavior180, 181. At the cellular
level, Bmal1 forms a heterodimer with Clock, another member of the bHLH-PAS family,
through their PAS protein-protein interaction domain. The heterodimer constitutes the
positive limb of the circadian feedback loop machinery to initiate the transcription of
target genes containing E-box cis-regulatory enhancer sequences and are highly
selective for those with the sequence CACGTG182 including the period (per1, per2 and
per3) paralogous member of the PAS protein family and cryptochrome (cry1 and
cry2)182-184, members of the vitamin B2-based blue light photoreceptor/photolyase family.
After delays imposed by transcription, translation and posttranslation modification, the
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negative limb of the feedback loop is comprised of the heteromultimer formed by per, cry
and other proteins that translocate back in the nucleus and directly abrogate the
transcriptional activity of the Bmal1:Clock complex184-186. This inhibition is believed to be
mainly caused by the Cry proteins, probably by repressing histone acetyl transferase
(HAT) activity187, 188 while the translocation of the complex has been attributed to one or
more per proteins184, 187. Phosphorylation of Per and Cry and subsequential degradation
partly by casein kinase I epsilon and delta (CKI ε/δ) result in the Bmal1/Clock
heterodimer being released from inhibition and therefore free to initiate transcription
again189-191. The Bmal1/Clock heterodimer activates another core clock gene creating yet
another positive and negative feedback loop. Bmal1/Clock still constitute the positive
limb while rev-erbα, which codes for an orphan nuclear receptor192 constitutes the
negative limb. Just like per and cry, rev-erbα contains E-box enhancer in the promoter
region which allows binding and activation by Bmal1/Clock193,

. Rev-erbα has been

194

shown to inhibit Bmal1 transcription by binding the retinoic acid-related orphan response
elements (ROREs) in the promoter region193,

195, 196

. It has also been shown that

disruption of rev-erbα significantly affects Clock and Cry1193. The rev-erbα negative limb
is unlike the cry-per negative limb because it only inhibits Bmal1 instead of inhibiting the
Bmal1/Clock Complex. The inhibitory effect of Cry-per on Bmal1/clock also acts to inhibit
rev-erbα transcription. Competing with rev-erbα at the ROREs is Rorα; whereas rev-erbα
acts to inhibit Bmal1 transcription, Rorα activates Bmal1 transcription through two
conserved Rorα conserved elements197. More ROREs were shown to regulate Bmal1
expression. Since the Rev-erb and the ROR families recognize the similar response
element with opposite effect on Bmal1 transcription, Guillaumond et al. investigated the
possibility that each member of the both families can regulate Bmal1 expression. Within
the Rev-erb family both Rev-erbα and Rev-rebβ were shown to inhibit Bmal1 expression
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and the RORs members (RORα, RORβ, RORγ) were shown to activate Bmal1
transcription198.
At the molecular level, the combination of transcription, translation and posttranslational
modification of the core clock genes results in a daily rhythmic expression, or circadian
rhythms of those genes. In mammalian physiology, circadian rhythm is driven by a
central pacemaker located in the suprachiasmatic nuclei (SCN) of the hypothalamus.
The SCN is controled by photic cues from the retino-hypotalamic tract which in turn
control and synchronizes clock genes in peripheral tissues. Although the SCN controls
rhythmicity in the whole organisms, rhythmicity is also maintained within individual
tissues and even at the cellular level199, 200. The phases within peripheral tissues have
been shown to be delayed by approximately four hours from the SCN. Lesion of the
SCN rendered rats behaviorally arrhythmic201. Hormonal signals such as glucocorticoids
and restricted feeding can uncouple the phase of peripheral tissues from the SCN202, 203.
In a study by Damiola et al., restricting mice from food during the day on a 12-h light/12h dark cycle resulted in a 12 hour shift of clock genes expression in the peripheral tissue
while the expression in the SCN remained unchanged, and Stocklan et al. demonstrated
that food restriction during the light not only shifts the phase of the clock genes
expression by 10 hours after 3 days of restricted feeding in rats but it also alters their
locomotor activities. Both findings from Damiola and Stocklan suggest that feeding is an
important cue to determine clock genes expression pattern in peripheral tissues.
Even though the circadian machinery in the SCN and peripheral tissues is well
understood, the mechanisms downstream of the clock machinery that regulate
metabolism and physiological processes is still being heavily investigated. Ramsey et
al. described in 2007 that there is an approximate of 5% to 10% of the transcriptome has
shown to be have a 24 hour variation in the SCN, heart, vasculature and fat. Since then,
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more genes have been shown to be under control of the clock core genes now
estimated at over 10%. Albumin gene D-site binding protein (DBP) belongs to the PAR
leucine zipper transcription factor family; it increases the transcription of many genes
containing an insulin-response element in the liver204. It is endogenously rhythmic and its
expression is not influenced by light. DBP mRNA expression does not change with a
short exposure to light. Deletion of DBP does not alter rhythmicity. However, mice
lacking DBP have been display significant differences in circadian locomotor activity205.
(Although DBP is a clock control gene, its regulation requires both Bmal1 and Clock).
Another group of genes that are controlled by clock genes and are involved in metabolic
processes such as lipid homeostasis in the vascular system is the peroxisome
proliferator-activated receptor (PPAR)206. PPAR are member of the nuclear receptor
superfamily and there have been three types of PPAR described: PPARα,
PPARβ/PPARδ and PPARγ. PPARα, which is highly expressed in the liver and brown
adipose tissue, acts as a lipid sensor in the liver. It activates the transcription of specific
genes in response to an influx of fatty acids207
Bmal1 and Clock are the two transcription factors that set off the circadian rhythm
machinery. While the global deletion of Clock in mice does not affect circadian rhythm
but affect the response to light208, global deletion of Bmal1 in mice disrupts behavior and
molecular rhythm183. Bmal1 null mice have been shown to have a reduced lifespan and
pathologies associated with pre-mature aging and an increase in oxidative stress. Bmal1
is involved in vascular pathologies. It has been associated with prothrombotic
phenotype209. A study from Somanath et al. had shown that when using the mesentery
artery to induce thrombosis, the time to thrombotic occlusion in Bmal1 KO mice was
shorter than in wildtype control. Bmal1 has been shown to play an important role in
vascular pathologies210. It has been associated with flow dependent vascular
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remodeling211, aortic vascular stiffness, transplant arteriosclerosis and increased
superoxide and endothelial nitric oxide synthase uncoupling in aorta.
1.4.2. Bmal1 and cardiovascular disease
Bmal1 and other core clock genes are expressed in peripheral tissues212, including
cardiovascular organs: heart, aorta and kidney213,

214

. Data suggest that approximately

10% of genes in peripheral organs exhibit circadian expression in the heart215,

216

and

vascular tissues217. These data bring in a new perspective on the function of peripheral
clocks in different organs or even at the cellular level. Heart rate, blood pressure,
endothelial function, and fibrinolytic activity are all cardiovascular parameters that exhibit
circadian variations. An alteration of Bmal1 has been shown to be involved in vascular
pathologies210. When the germline Bmal1-/- mice underwent a chronic reduction in blood
flow in the common carotid artery, those mice developed a wall thickness that was more
pronounced then their littermate control. They had also developed vascular remodeling.
However, instead of narrowing the lumen as observed with the control, those mice had
an increase in lumen diameter which was accompanied with a development of a
thrombosis211. Another study from Anea et al. had shown that Bmal1-/- mice have an
increase in vascular stiffness and a decrease in compliance. They had also shown that
Bmal1-/- mice have an increase of MMP2 and MMP9 activities 3 days after of common
carotid artery ligation. MMP9 activity was also increase in non-ligated artery218.
Transplant model demonstrated that a transplant of aorta from Bmal1-/- mice into control
mice lead to transplant arteriosclerosis observed by intimal hyperplasia and wall
thickness while the transplant had only induced inward remodeling between control and
control219. Bmal1-/- mice had a reduced endothelial function due to an increase in
oxidative stress220.
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Circadian expression of clock genes has been shown to be expressed in vascular
endothelial cells and in vascular smooth muscle cells214. Data has shown that VSMC
stimulation with ANGII induces clock genes expression. The time of stimulation by AngII
can be considered as a zeitbeger time in VSMC214. Xie et al. had demonstrated that
tissue specific deletion of Bmal1 in smooth muscle cells lowered and altered blood
pressure circadian rhythm221. Although, there are studies that have looked at the role of
Bmal1 in vascular diseases, those studies involved a global knockout of Bmal1, making
it difficult to assess the role that Bmal1 plays in the vasculature itself without altering its
expression in other tissues and cells. Studies from Xie mentioned above are more
insightful by looking at the role of smooth muscle Bmal1 in the regulation of blood
pressure. Since they have used smooth muscle cells specific Bmal1 KO and blood
pressure is regulated in small vessel such as mesenteric arteries and smooth muscle
cells are the biggest component of those vessels. Therefore, a specific deletion of Bmal1
in smooth muscle is most appropriate to study the role of Bmal1 in blood pressure
regulation. Smooth muscle cells are big player in AAA formation and AAA ruptures have
been shown to have time of the day variations. This could imply a role for clock genes in
AAA formation. Whether Bmal1 plays a role in aortic aneurysm formation has not been
showed yet. Therefore, there is the need to understand the role that smooth muscle
Bmal1 could play in the formation of AAA.
1.5. Scope of the dissertation
Abdominal aortic aneurysm (AAA) is a multifactorial disease characterized by a
permanent segmental, abnormal dilation of the aorta1. This permanent dilation is due to
an increase in elastin and ECM degradation; an increase in inflammatory cell infiltration;
and smooth muscle cells apoptosis22, 23. In human AAA, MMP expression increases in
VSMCs39, and thus play a central role in the development of AAA. MMPs degrade the
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ECM of the vasculature including elastin, and the increase in MMPs is induced by an
increase in inflammatory cells and cytokines, which are secreted by smooth muscle
cells40,

41, 43, 46, 47

. The precise mechanisms of aortic aneurysm formation are not well

understood making it very challenging to develop a therapeutic treatment. Therefore, the
only treatment has been an emergency surgery, which has a mortality rate of more than
50%. Therefore, deciphering the molecular mechanism underlying aneurysm formation
is urgently needed in order to identify new pharmacological therapeutic targets.
As previously mentioned, Bmal1 is an obligatory core clock gene and a transcriptional
factor; it regulates genes essentials for normal circadian rhythm in physiology and
behavior222. Bmal1 is expressed in the SCN and peripheral tissues including VSMC, and
is essential for normal vascular functions223 . Alteration of Bmal1 has been associated
with

different

vascular

pathologies

such

as

vascular

stiffness218,

transplant

arteriosclerosis219 and flow-dependent vascular remodeling211. However, the role of
Bmal1 in AAA formation has yet to be studied. AAA dissection and rupture have been
shown to have circadian variability224, which would suggest an involvement of clock
genes, and Bmal1 deletion has been shown to increase oxidative stress and MMPs,
which are increased in human AAA VSMC43, 218, 220. Therefore, the purpose of this study
was to investigate the role that vascular Bmal1 plays in AAA formation. The initial
hypothesis was that Bmal1 deletion would exacerbate AAA formation. Therefore, we
used smooth muscle cells specific Bmal1 knockout mice to test our hypothesis.
However, the hypothesis was rejected because Bmal1 deletion from smooth muscle
cells showed a complete protection from AAA formation. We moved to understand the
mechanism of protection.
Different experimental approaches were taken to understand and determine the
mechanism of protection, and they are presented in chapter 2. The results and their
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explanations are presented in chapter 3. The discussion and limitations of the project are
presented in chapters 4.
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CHAPTER 2
Materials and Methods
2.1. Experimental Design

ultrasound

SBP

DOCA
Blood collection
mRNA
Protein by ELISA
IHC
Gel Zymography
In Situ Zymography

ultrasound

ultrasound

ultrasound

SBP

Euthanasia
tissue collection
Aorta picture and external
Diameter measurement

Day 0

Day 1

Day 7
0.9% NaCl
water

Day 14

Day 20

Day 21

Figure 1: Diagram showing the time line and different methods used
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2.2. Animals
Four or eight to nine month old male smooth muscle cells Bmal1 Knockout mice (SM
Bmal1-/-) and littermate control were used for this study. SM Bmal1-/- mice were
generated by crossing Bmal1flox/flox mice with smooth muscle cell specific SM22α-Cre
knocked-in mice; both were purchased from Jackson Laboratory. Homozygous
Bmal1flox/flox mice possess a loxP sites flanking exon 8 which encode for Bmal1 binding
site to E-box. To generate the SM22α-Cre knocked-in mice, a modified Cre recombinase
under the control of SM22α promoter was introduced into B6SJLF2 donor oocytes.
When Bmal1flox/flox mice were crossed with SM22α-Cre transgenic mice, the presence of
Cre resulted in the deletion of the flanked exon 8 of Bmal1. Since SM22α has been
shown to be smooth muscle cells specific225, it is expressed in aorta, esophagus,
intestine, trachea and uterus. SM22α is also expressed in the heart and skeletal
muscles226. Bmal1 is specifically deleted in smooth muscle cells including the aorta.
C57B6/J mice used in this study were purchased from Jackson Laboratories. They were
left for acclimatization for 2 weeks in light box: The light box is set for 12:12 light cycle:
12 hours of light and 12 hours of dark. The light was set to be turned on at 6:00am and
turned off at 6:00pm. The mice were killed at 4 different time point: ZT5, ZT11, ZT17,
ZT23 were ZT stand for Zeitgeber Time: the number of hours after the light is turned on;
making ZT5 and ZT11 day time and ZT17 and ZT23 night time.
2.3 DOCA/AngiotensinII pump implantation plus salt
To induce Aortic Aneurysm, a 50 mg Deoxycorticosterone Acetate pellet (DOCA, 21-day
release, Innovative Research of America, Sarasota, FL) or 1000 ng/kg/day Angiotensin II
(Sigma-aldrich, St. Louis, MO) in osmotic minipump (Alzet mini pump 28 days release,
Alzet, Cupertino, CA) was administered subcutaneously; the mice were also given
drinking water containing 0.9% NaCl and 0.2% KCl for 21 days for DOCA and 28 days
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for Angiontensin II plus salt. To perform the surgery, mice were anesthetized by
inhalation of isoflurane mixed with oxygen (3% isoflurane and 97% oxygen). Mice were
placed in the prone position with continuous anesthesia. Hair from the cervical area was
removed using Nair shaving cream and lateral incision was made. There, a pouch was
created to insert the pellet or the pump was placed subcutaneously in the thoracic spine
area. The wound was closed with suture and the mice monitored for recovery227, 228.
2.4 Blood Pressure measurement by tail cuff
Prior to DOCA or ANGII implantation, the systolic blood pressure was measured using a
non-invasive tail cuff method with automated monitor (CODA6, Kent Scientific
Corporation, Connecticut, USA). Mice are placed in a restrainer to keep mice from
excessive movements with the tail still on the outside. The holder is then placed in a
heated platform at 370C then two cuffs: the occlusion cuff (O cuff) and the volume
pressure recording cuff (VPR cuff) are placed around the tail to record blood pressure.
Blood pressure measurements were recorded for 5 consecutive days at the same time
of the day and averaged. Unusually high or low blood pressure collected during the 5
days were considered outliers and therefore excluded from the average blood
pressure73. The measurements were repeated on the third week for DOCA plus Salt and
on the fourth week for ANGII plus Salt.
2.5. Aorta Inner diameter assessments by ultrasound
The aorta inner diameter was first measured prior to DOCA or Angiotensin II pump
implantation and monitored weekly thereafter. The inner diameter was measured via
ultrasound imaging system using VEVO 2100. In order to perform the ultrasound, mice
were first anesthetized by inhalation of isoflurane mixed with oxygen (3% isoflurane and
97% oxygen). Upon loss of total locomotion, mice were placed in the supine position
onto 37oC heated platform. The hair in the abdominal area was removed using Nair
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shaving cream. Isoflurane was continuously maintained for the whole procedure.
Warmed ultrasound transmission gel was placed in the entire shaved area and the
transducer was placed just below the ribs cage. The maximal inner diameter of the aortic
suprarenal area was measured from ultrasound image acquired from a cine loop of 100
images. Hepatic artery, hepatic vein, and bile duct were used as marker to acquire
image in the same location in each mouse227.
2.6. Blood Sodium and Potassium Measurement
After the mice were euthanized, freshly drawn blood from a cardiac puncture with a
syringe was subsequently placed in an I-STAT E3+ cartridge (cat# SKU: 600-9004)
without anti-coagulant. The cartridge was placed into a VetScan I-STAT1 handheld
analyzer by ABAXIS and sodium and potassium concentrations were determined.
2.7. mRNA isolation and Real-time PCR
Aorta was removed from mice treated with DOCA plus Salt for 7 or 21 days and from
non-treated mice. The aorta was then placed in RNAlater RNA stabilization Reagent
(QIAGEN cat # 76106). RNA was extracted using RNeasy plus mini kit (QIAGEN) as
follows: The whole aorta was placed in a homogenizer with 300µl of RLT buffer
containing β-Mercaptoethanol (for each 1 ml of RLT buffer, we added 10 µl of βMercaptoethanol), the tissue was homogenized until complete dissipation into the
solution. Only debris of the tissue could be seen through the homogenizer. 580 µl of
water and 20 µl of proteinase K (Invitrogen cat # AM2542) were then added followed by
pipetting up and down for about 10 times using a syringe and needle. The sample was
sucked up into the syringe and transferred in a 1.5 ml Eppendrof tube, then heated in a
heating block at 550C for 10 minutes then centrifuged at 40C at full speed for 5 minutes.
The supernatant was removed carefully without touching the pellet and transferred into a
1.5 ml eppendrof tube. Then 400 µl of 100% ethanol was added to the sample and
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mixed by pipetting up and down. Then 700 µl of the sample was transferred into RNeasy
spin column and centrifuge at 8000xg for 15 seconds and the flow-through was
discarded. The remainder of the sample was added to the same spin column and
centrifuged. The flow-through was then discarded. 700 µl of RW1 buffer was added to
the spin column then centrifuged for 15 seconds at 8000Xg, the flow-through was
discarded. Then 500 µl of RPE buffer was added to the RNeasy spin column at 8000xg
for 15 seconds. Another 500 µl of RPE buffer was added to the RNeasy spin column and
centrifuged at 8000xg for 2 minutes. The flow-through and the collection tube were
discarded and the column placed in a new collection tube and centrifuged for 1 minute at
full speed to allow the membrane to dry. The collection tube was discarded and the spin
column was placed in a new 1.5 ml collection tube and 30 µl of Rnase-free water was
added directly to the spin column membrane and centrifuge for 1 min at 8000xg to elute
the RNA. Then the RNA concentration was measured using a nanodrop. cDNA was
generated by reverse transcriptase PCR as follows:
-RNA, distilled water; random primer and dNTP were mixed together in a PCR tube and
placed in a PCR machine:
Step 1: 650C for 5 minutes
While step 1 was running, in an epperdorf tube 5x buffer, RNaseout, RT and water were
mixed together and placed in the PCR tube while sample was in set 2.
Step 2: 40C for 5 minutes
Step 3: 370C for 1 hour
Step 4: 700C for 15 minutes
Step 5: 40C
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cDNA generated was then diluted with distilled water for a final concentration of 10ng/µl.
The amount of RNA added depended on the concentration of RNA and the total amount
of desired cDNA generated with the maximum amount being 5000ng.
For real time PCR, the samples were prepared as followed:
Forward primer, Reverse primer, 5x buffer, MgCl2, dNTP, SYB green, Taq Pol and water
were mixed: vortexed and centrifuged together in a 1.5 ml epperdorf tube. 22µl mixture
was then aliquoted in 96 well PCR plate (Phenix Research Products, USA lot# 466568)
and 3µl or 30ng of the cDNA was added in each well. The plate was centrifuged and
placed in PCR machine with the following steps:
Step1: 950C for 3 minutes
Step2: 950C for 15 seconds
Step3: 600C for 1 minute
Step4: Go to step 2 40 times
Step5: Melt curve 60.0 to 95.0 with 0.5 increase for 5 seconds
Step6: 200C for 5 minutes
Real-time PCR was performed for quantification of genes expression of tissue inhibitor
of metalloproteinases (TIMPs)1, 2, 3 and 4, the mineralocorticoid receptor (MR), Bmal1,
Rev-erb, Per1, and Cry1.
2.8. Immunohistochemistry
For immunohistochemistry studies, the aorta was fixed first by incubating the sample in
70% alcohol for 48 hours then in 5% formaldehyde for 24 hours, following which it was
embedded in paraffin. With the use of a microtome, the embedded tissues were cut in
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series with a thickness of 5µm. Once a section was cut, with the use of a pencil it was
held then placed in warmed water and picked up with a slide. Finally the tissue’s slides
were placed on a heated platform to dry.
The tissue was first stained for elastin with an elastin staining kit (Van Gieson staining,
Richard-Allan Scientific CAT # 87017). Samples were deparaffinized by heating at 600C
for 2 hours, this was followed by a series of incubation for hydration: 2 times in xylene for
15 min each time, 2 times in 100% ethanol for 5 minutes each times then in 95% ethanol
for 5 min and 85% ethanol for 5 minutes followed by 70% and 50% ethanol for 5 minutes
and water for 5 minutes. Samples were stained in working elastic stain solution for 30
minutes then rinsed in running tap water for 1 minute. The samples were then
decolorized in working differentiating solution followed by a rinsed in tap water. The
samples were then placed in sodium thiosulfate solution for 1 minute, then rinse with
water for 3 minutes. They were then stained with Van Gieson stain solution for 3 minutes
followed twice by dehydration in anhydrous alcohol for 1 minute each then cleared in
clearing reagent 3 times for 1 minute each and mounted.
For TIMP4 staining, the section were deparaffinized, rehydrated, and treated with low pH
antigen retrieve buffer (Vector Laboratory, Burlingame, CA) to retrieve antigen. Sections
were treated with 3% H2O2 to quench endogenous peroxidases. After blocking
endogenous background with Avidin/Biotin blocking kit (Vector/Laboratories) and nonspecific binding (normal goat serum, Vectastain ABC Kit), slides were incubated with the
TIMP4 primary antibodies (AssayBioTech) overnight at 4oC. Slides were then incubated
with biotinylated secondary antibody (VECTASTAIN, ABC kit, elite). This incubation was
followed by signaling detection which required samples to be subjected to the procedure
of VECTASTAIN Elite ABC system (Vector Laboratories). Immunoreactivity was
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visualized by DAB (DAKO North America Inc, Carpinteria, CA) followed by
counterstaining with hematoxylin.
2.9. Gel Zymography
The aorta was freshly dissected and equilibrated in PBS for 30 minutes, then incubated
in Krebs buffer for 24 hours at 370C. The medium containing MMPs loaded in a 2%
gelatin zymogram gel : 10% gel (Acrylamide 29:1, 4x Separate gel buffer pH 8.8, gelatin,
10% APS, TEMED), stacking gel (Stacking buffer, Acrylamide 29:1, 10% APS,
TEMED).The gel ran at 100v until the dye front reached the bottom of the gel. It was
then incubated 2 times in wash buffer (1M Tris, 1 M CaCl2, 10mM ZnCl2, 2% Na2N3,
Triton X-100) at 370C with shaking, followed by incubation in reaction buffer (1M Tris, 1
M CaCl2, 10mM ZnCl2, 2% Na2N3, Triton X-100) at 370C overnight. After incubation, the
gel was washed 3 times with water at room temperature with shaking, stained with
GelCode Blue Safe Protein and destained with water. The gel was scanned for
visualization.
2.10. In Situ Zymography
To detect MMP/Gelatinases activities, the slides containing sections of paraffin
embedded aorta were heated at 59oC overnight, deparaffinized in xylene and rehydrated
in graded alcohol. Samples were incubated with a DQ gelatin fluorescein conjugate
(EnzChek Gelatinase/Collagen Assay Kit, Molecular Probes CAT# E12055). Samples
were first equilibrated in reaction buffer (0.5 M Tris-HCl, 1.5 M NaCl, 50mM CaCl2, 2 mM
sodium azide, pH 7.6) for 5 minutes. Substrate was prepared by dissolving 1mg DQ
gelatin in 1.0 ml of water then further diluted (1:200) in reaction buffer to make the
reaction mixture. Each sample was incubated with 100µl of the reaction mixture at 370C
for 2 hours in the dark. The slides were then washed with PBS 3 times for 2 minutes
each. The slides were then fixed in 4% formaldehyde for 10 minutes in the dark washed
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with PBS 3 times for 5 minutes each. The slides were then counterstain with DAPI then
mounted229.
2.11. ChIP Assay
Freshly dissected aorta was allowed to equilibrate in PBS for 30 minutes and fixed in 1%
formaldehyde in PBS for 1 hour, following which 2% glycine in PBS was added in the
sample. The tissue was frozen in liquid nitrogen and pulverized until a powder was
formed. Then lysis buffer (0.1 M NaCl, 50mm Mop-NaOH pH 7.0, 1M EGTA, 0.1%
Tween 20, 2mM MgCl2,0.5mM DTT(TCEP) was added to the sample and allowed to
equilibrate at room temperature. The sample was centrifuged and the pellet collected
and washed twice with the lysis buffer. The sample was then treated with mung bean
nuclease at room temperature followed by sonication (36% power) and centrifugation at
4oC. The supernatant was diluted 10 fold in CHIP dilution buffer (5% sodium
deoxycholate, Triton X-100, 0.5 M EDTA, 1M Tris HCl pH8.0, 5M NaCl) supplemented
with proteases and phosphatases inhibitor (PMSF, aprotinin, leupeptin, pepstatin, DTT,
NaF, Na3VO4). Salmon sperm DNA/protein A/G 50% slurry was added to pre-clear the
sample with rotation at 40C. Sample was then centrifuged and the supernatant collected
and incubated with immunoprecipitating 3ug Bmal1 or non-specific IgG overnight at 40C.
Salmon sperm DNA/ protein G-agarose slurry was added to collect Ab/Histone complex
by rotation at 40C. The sample was centrifuged and the pellet was collected. A series of
washes followed: 2 times wash with low salt (10% SDS,Triton-X100, 0.5M EDTA, 1M
Tris-HCl pH 8.0, 5M Nacl), 2 times High salt (10% SDS,Triton-X100, 0.5M EDTA, 1M
Tris-HCl pH 8.0, 5M Nacl), 2 times LiCl (5M LiCl, NP-40, Deoxychloric Acid, 0.5M EDTA,
1MTris-HCl pH 8.0) and 3 times 1X TE(1M Tris-HCl, 0.5 M EDTA). The
immunocomplexes were eluted by adding elution buffer (1M Tris-HCl pH 8.0, 5M NaCl,
0.5M EDTA, 10% SDS) to the pelleted complex, then centrifuged following which the
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supernatant was collected. 5M NaCl was added to the supernatant and histone crosslink
reverse by heating at 650C. 0.5 M EDTA, 1M Tris-Cl pH 6.5 and 10mg/ml of proteinase K
were added to the sample which was followed by incubation at 450C. DNA was extracted
by 1 volume of phenol/chloroform and twice by half volume of straight chloroform. 1/10
Volume of 3M NaOac, 2 volumes of 100% ethanol and 1 ul of glycogen were added to
the DNA extract which was stored at -800C. Then the product centrifuged at 40C. The
pellet was washed with 75% ethanol and resuspended in TE.
1 µl of the sample used for PCR as followed:
Step1: 94o for 3:00
Step2: 94o for 0:30
Step3: 55o for 1:00
Step4: 72o for 0:30
Step5: Go to step2 for 40 times
Step6: 72o for 10:00
The product was run in 1.5% agarose gel
2.12. TIMP4 Promoter Cloning
A mouse Bacterial Artificial Chromosome (BAC) clone containing the mouse TIMP4
promoter was purchased from Lifetechnologies. A small portion of the glycerol stock was
streaked on a LB plate containing 12.5µg/ml chloramphenicol and incubated at 37oC
overnight. A single colony was isolated and incubated in 10ml of LB 12.5µg/ml
chloramphenicol at 37oC overnight with shaking. The culture was in 1.5 ml tubes and
centrifuged for 1 minute at 14000 rpm. The supernatant was discarded. The pellet was
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resuspended in 200 µl of solution I (50 mM Tris pH 8.0 with HCl, 10 mM EDTA,
100µg/ml RNase A). Then 200 µl of solution II (200 mM NaOH, 1%SDS) was added and
gently mixed, it was followed by adding 200 µl of solution III (3.0 M Potassium Acetate,
pH 5.5). The sample was mixed by inverting the tube gently. A white precipitate had
formed. The tube was then centrifuged for 10 minutes at 14,000rpm. The supernatant
was transferred to a new tube without transferring any pellets. 900 µl of 100% ethanol
was added to the supernatant and mixed well by inverting the tube, followed by
centrifugation for 20 minutes at 14,000 rpm. The supernatant was removed and
discarded. 100 µl of ice cold 75% ethanol was added to the pellet then centrifuged for 30
sec. The supernatant was completely removed from the pellet and dried for 20 minutes.
The pellet was resuspended in 50 µl of distilled water. 1 µl of the sample was used for
PCR to amplify the product as followed:
Step1: 94o for 3:00
Step2: 94o for 0:30
Step3: 55o for 1:00
Step4: 72o for 2:00
Step5: Go to step2 for 40 times
Step6: 72o for 10:00
1 µl of the sample was used to verify the product in 1.5% agarose gel.
The PCR product was then ligated to a TA vector as follows: in a 0.5 µl PCR tube, 5 µl of
2x Rapid Ligation Buffer was mixed, 1µl of the vector, 1 µl of the PCR product and 1µl of
T4 DNA ligase and nuclease free water was added to a final volume of 10µl. The
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reaction was mixed by pipetting and incubated at room temperature for 1 hour at room
temperature.
Tube containing E. coli competent cells was placed on ice until thawed. The cells were
mixed by gently flicking the tube. 50 µl of cells was transferred in the tube containing the
ligation reaction. The tube was then gently flicked and placed on ice for 20 minutes. The
tube was placed in a water bath at 420C for 50 seconds and placed on ice for 2 minutes.
900µl of SOC medium was added to the reaction and incubated for 1.5 hours at 37oC
with shaking. 100 µl of the transformation culture was plated in a LB plate containing
ampicillin/IPTG/X-Gal then incubated overnight at 37oC. A single colony was picked and
incubated in 10ml of LB 12.5µg/ml chloramphenicol at 37oC overnight with shaking. The
culture was in 1.5 ml tubes and centrifuged for 1 minute at 14000 rpm. The supernatant
was discarded. The pellet was resuspended in 200 µl of solution I. Then 200 µl of
solution II was added and gently mixed, followed by adding 200 µl of solution III. The
sample was mixed by inverting the tube gently. A white precipitate had formed. The tube
was then centrifuged for 10 minutes at 14,000rpm. The supernatant was transferred to a
new tube without transferring any pellets. 900 µl of 100% Ethanol was added to the
supernatant and mixed well by inverting the tube, followed by centrifugation for 20
minutes at 14,000 rpm. The supernatant was removed and discarded. 100 µl of ice cold
75% ethanol was added to the pellet then centrifuged for 30 sec. The supernatant was
completely removed from the pellet and dried for 20 minutes. The pellet was
resuspended in 50 µl of distilled water. One µl of the sample was used to verify the
product by PCR as previously discribed. The sample was then digested with KPNI and
XHOI and ran in a 1.5% agarose gel to verify the product.
The insert (product) was cut from the gel and placed in a 1.5 ml tube. 10µl of the
membrane binding per 10µg of gel solution was added then vortexed and incubated at
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65oC until the gel was completely dissolved. The dissolved gel mixture was transferred
into SV Minicolumn inserted in a collection tube and incubated at room temperature for 1
minute. The mixture was then centrifuged at 16,000xg for 1 minute. The flow-through
was discarded. 700µl of the membrane solution with ethanol was added and centrifuge
at 16,000xg for 1 minute. Another 500µl of membrane solution was added and
centrifuged at 16,000xg for 5 minutes. The flow-through was discarded and the column
was centrifuged for 1 minute with lid open. The minicolumn was transferred into a new
1.5 ml tube and 50 µl of nuclease-free water was added to the column and incubated at
room temperature for 1 minute then centrifuged at 16,000xg for 1 minute. While running
this experiment, the pGL3 vector was also digested using KPNI and XHOI. Then the
DNA purified from the cut gel was ligated to the digested pGL3 vector at 37oC for 1 hour.
The ligated product was then transfected into competent E.coli cells as described above.
A single colony was picked from a freshly streaked plate and inoculated in 5 ml LB
medium containing chloramphenicol overnight at 370C with shaking. The culture was
diluted 1/500 in LB medium and 200 µl of the diluted culture was inoculated with 100 ml
of medium at 370C overnight with shaking. Culture was transferred into plastic centrifuge
tube. The bacterial cells were harvested by centrifugation at 6000 x g for 15 min. at 40C.
The bacteria were resuspended in 10 ml Buffer P1; 10 ml of buffer P2 was added, then
mixed vigorously by inverting 6 times, then incubated at room temperature for 5 min.
Chilled Buffer P3 was then added to the lysate, and mixed vigorously by inverting 6
times. The lysate was poured into the barrel of the QIAfilter cartridge then incubated at
room temperature for 10 min. without inserting the plunger. The cap was then removed
from the cartridge and the plunger inserted slowly and the cell lysate was filtered into a
50 ml tube. Then 2.5 ml of buffer ER was added to the filtered lysate and mixed by
inverting the tube 10 times, then incubated on ice for 30 min. QIAGEN-tip 500 was
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equilibrated by adding 10 ml Buffer QBT and allowed the column to empty by gravity
flow. The filtered lysate was placed into the QIAGEN-tip and allowed to enter the resin
by gravity flow. The QIAGEN-tip was washed 2 times with 30 ml Buffer QC. The DNA
was eluted with 15 ml of Buffer QN, then precipitated by adding 10.5 ml of isopropanol. It
was then mixed and centrifuged at 15,000 x g for 30 min at 40C. The supernatant was
removed. The DNA pellet was washed with 5 ml of 70% ethanol and centrifuged at
15,000 x g for 10 min. The supernatant was removed without disturbing the pellet. The
pellet was air-dried for 10 minutes and redissolved in 500 µl of Buffer TE. Then the DNA
concentration was measured using the nanodrop and the Plasmid aliquoted and stored
at -800C.
2.13. TIMP4 Promoter Assay
The aorta of SMC Bmal1-/- and their littermate control were used to isolate vascular
smooth muscle cells. The cells were transfected with pGL3-TIMP4 luciferase vector and
TRL-SV 40 Renillla vector with Lipofectamine-Plus reagent (Life technologies). Cells
were first plated in twelve wells plate and incubated for 48 hours until the cells were
about 70% confluent. The medium was then changed to OPTI-medium for 3 hours
incubation at 370C. The DNA was pre-complexed with the plus reagent mixed and
incubated at room temperature for 15 min. In a second tube, Lipofectamine reagent was
diluted into OPTI-medium; next, this was combined with the precomplexed DNA, mixed
and incubated for 15 minutes at room temperature. The DNA-Plus –Lipofectamine
Reagent was added to each well containing fresh medium. The complexes was was
incubated overnight at 370C. The medium was then removed and incubated for 24 hour
at 370C with DMEM. After transfection was completed, the medium was removed and
passive lysis buffer (Promega CAT# E1941) was added to each well followed by shaking
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at room temperature. The lysed cells were centrifuge at 40C and the supernatant was
kept for the reading of the luciferase and renilla.
2.14. TIMP4 ELISA
2.14.1 Sample Preparation
After isolating the aorta from mice, the tissue was snap-frozen with liquid nitrogen and
stored at -800C until protein extraction. To extract protein from aorta, the frozen tissue
was homogenized using rotor homogenizer and RIPA buffer (25mM Tris HCl pH 7.6,
150mM NaCl, 1% NP-40, 1% sodium deoxylatecholate, 0.1% SDS) containing proteases
at 40C. The samples were centrifuged for 10 minutes at 16000g at 40C. The supernatant
was aliquoted and the protein concentration was measured by BCA protein assay with
Pierce BCA Protein Assay Kit.
2.14.2. ELISA
The capture antibody was diluted to working concentration in PBS. A 96-well microplate
was coated with 100 µl of the diluted capture antibody in each well. The plate was
sealed and incubated overnight at room temperature. The next day, the capture antibody
was aspirate from the wells and washed with wash buffer (0.05% Tween 20 in PBS, pH
7.2-7.4) 3 times. The plates was then blocked by adding 300 µl of block buffer (1% BSA
in PBS, pH 7.2-7.4) and incubated at room temperature for 1 hour; this step was
followed by washing the plate with wash buffer 3 times. 100 µl of the sample or
standards in reagent diluent (50mM Tris, 10mM CaCl2, 0.15M NaCl2, 0.05 Brij 35, pH
7.45-7.55) per well was added on the plate. The plate was covered and incubated at
room temperature for 2 hours. The standards were prepared by making a six point
standard curve with 2 fold serial dilutions with a highest concentration being 10,000
pg/mL and the lowest concentration 313 pg/mL. The plate was washed 3 times with
wash buffer after incubation. 100 µl of detection antibody diluted in reagent diluent was
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added in each well. The plate was covered and incubated for 2 hours at room
temperature. The plate was then washed 3 times with was buffer. Then 100µl of the
working dilution of streptavidin-HRP was added to each well. The plate was covered first
adhesive strip then with aluminum foil to avoid light and incubated for 20 minutes at
room temperature. After 20 minutes, the plate was washed three times with wash buffer.
100µl of substrate solution was added to each well and left to incubate for 20 minutes at
room temperature, the plate was again covered with aluminum foil to avoid light. 50 µl of
stop solution was added to each plate and tapped gently for mixing. The optical density
of each well was determined using a microplate reader. To correct imperfections in the
plate, 540nm wavelength was subtracted from the readings at 450nm.
2.15. Statistical Analysis
All data were expressed as mean ± S.E.M. Unpaired Student t-test was used for
comparison between two groups. One-way ANOVA followed by Newman-Keul’s posthoc analysis was used for the comparison among multiple groups. Two-way ANOVA
with repeated measures was used for comparison among multiple groups. Chi Square
analysis was used for comparing AAA, TAA, and rupture incidence. A P value of <0.05
was considered significant. A P value of >0.05 was considered non-significant (NS).
2.16. Study approval.
All animal procedures were approved by the Institutional Animal Care and Use
Committee of University of Kentucky.
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Table 1: List of Primers
Gene
MR

Primer

Sequence

Application

Forw ard

5'-ATGGAAACCACACGGTGACCT-3'

Real Time PCR

Reverse

5'-AGCCTCATCTCCACACACCAAG-3'

Real Time PCR

Forw ard

5'-CCAGAGCCGTCACTTTGCTT-3

Real Time PCR

Reverse

5'-AGGAAAAGTAGACAGTGTTCAGGCTT-3'

Real Time PCR

Forw ard

5'-ACGCTTAGCATCACCCAGAAG-3

Real Time PCR

Reverse

5'TTGGGACAGGGAGTGATCTTG-3'

Real Time PCR

Forw ard

5'ATCCCCAGGATGCCTTCTG-3'

Real Time PCR

Reverse

5'-CCCTCCTTCACCAGCTTCTTT-3

Real Time PCR

TIMP4

Forw ard

5'-TGTGGCTGCCAAATCACCA-3'

Real Time PCR

Reverse

5'-TCATGCAGACATAGTGCTGGG-3'

Real Time PCR

Bmal1

Forw ard

5′-CACTGTCCCAGGCATTCCA-3′

Real Time PCR

Reverse

5′-TTCCTCCGCGATCATTCG-3′

Real Time PCR

Forw ard

5′-TCGCCGGCTCTTCCAA-3′

Real Time PCR

Reverse

5′-TCAAGACACTGAAGCAAAAATCG-3′

Real Time PCR

Forw ard

5′-TCGAAACCAGGACACCTTCTCT-3′

Real Time PCR

Reverse

5′-GGGCACCCCGAAACACA-3′

Real Time PCR

Rev-erbα

Forw ard

5′-CCCTGGACTCCAATAACAACACA-3′

Real Time PCR

Reverse

5′-GCCATTGGAGCTGTCACTGTAG-3′

Real Time PCR

TIMP4

Forw ard

5'-CCT ACT TGT TTT ACA CAT GGA ACC-3'

CHIP 1

Reverse

5'-GTT TAC AGA CAG CAA AAT TTA CCC TT-3'

CHIP 1

TIMP4

Forw ard

5'-CAC CGC TAA GAA GAT TTT TGT TCT-3'

CHIP 2

Reverse

5'-TGA ACT GGA CAG AGA TAG GCC T-3'

CHIP 2

Forw ard

5'-TAA GAA AGT AAA CGC TTT CCC AA-3'

CHIP 3

Reverse

5'-ATC AGC TCA GCC TTG TCA CTT-3'

CHIP 3

TIMP4

Forw ard

5'-AAG CCA CAC TAG CAG GTG AAG-3'

CHIP 4

Reverse

5'-CGA ACT CTT TTC TCC ATT AAG TAG GA-3'

CHIP 4

TIMP4

Forw ard

5'-TGA CAT CCT TCC CTA CCA CC-3'

CHIP 5

Reverse

5'-CAA GAG CTA GTG AAG GGA AGC A-3'

CHIP 5

TIMP4

Forw ard

5'-TTT GGT CAA TTT GTC AAA ATA CAA TG-3'

Cloning TIMP4 Promoter

Reverse

5'-GAC ACT GCA GAG CCC CAG-3'

Cloning TIMP4 Promoter

TIMP1

TIMP2

TIMP3

Cry1

Per1

TIMP4
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CHAPTER 3
RESULTS

3.1. Deletion of Bmal1 in vascular smooth muscle cells protects from
mineralocorticoid agonist plus salt induced aortic aneurysm
Liu et al. had previously demonstrated that administration of mineralocorticoid receptor
agonists, deoxycorticosterone acetate (DOCA) or aldosterone, when combined with high
salt, induces aortic aneurysms227. To determine the role of vascular smooth muscle
Bmal1 in aortic aneurysm formation, we administered DOCA plus salt to 4-month old
male SM-Bmal1-/- and littermate control mice for 21 days. The increase in the external
diameter of the abdominal and thoracic aorta by DOCA and salt administration was
significantly suppressed in the SM-Bmal1-/- mice (Fig.2A). Eight out of 26 control mice
had over a 50% dilation in abdominal aorta; however only one out of 25 SM-Bmal1-/- had
this.

None of the SM-Bmal1-/- mice showed thoracic aorta dilation (Fig.2 A). The

incidence of aortic aneurysms was significantly decreased from 30.7% in control mice to
4% in the SM-Bmal1-/- mice (P<0.01); the incidence of thoracic aortic aneurysms (TAA)
was decreased from 11.5% in control mice to 0% in the SM-Bmal1-/- mice ; and rupture
incidence went from 7.6% to 0% (Fig. 2B). Fig. 3 shows photographs of a normal aorta
from the SM-Bmal1-/- mice and a typical aneurysmal aorta from the control mice
administered with DOCA and high salt.
Mineralocorticoid receptors agonists plus salt induced aortic aneurysm in mice showed
that AAA formation and severity was aged dependent; therefore, we investigated
whether deletion of Bmal1 in smooth muscle will still afford the same protection in older
(8 months) mice. A dramatic protective effect by Bmal1 deletion was observed.
Ultrasound quantification of the intraluminal diameter of the abdominal aorta illustrated
that DOCA plus salt induced a time- dependent dilation in the control mice and that
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dilation was significantly suppressed in the SM-Bmal1-/- mice. The increase in the
intraluminal diameter (Fig. 4A; P<0.001) and external diameter (Fig. 4B; P<0.001) of
aorta were much more pronounced in control mice than in SM-Bmal1-/- mice. The aortic
aneurysm incidence was drastically decreased from 68.7% in the control to 0% in SMBmal1-/- mice (P<0.001), and TAAs were decreased from 31.2% in control mice to 0% in
SM-Bmal1-/- mice (P<0.05) (Fig. 4C). Moreover, no rupture occurred in the 16 SMBmal1-/- mice while 2 of 16 control mice died of rupture (Fig. 4C). Fig. 5 shows
photographs of a normal aorta from the SM-Bmal1-/- mice and a typical aneurysmal aorta
from the control mice administered aldosterone and high salt.
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Maximal External
Diameter of Aorta(mm)

A

3.0

**

2.5

*

2.0
1.5
1.0
0.5
0.0
WT

KO

WT

Abdominal Aorta

B

40

KO

ThoracicAorta

**

WT
KO

Incidence (%)

30.7%
(8/26)

30
NS
20
10

11.5%
(3/26)
4%
(1/25)

0%
(0/25)

0
AAA

TAA

NS
7.6%
(2/26)
0%
(0/25)

Rupture

Figure 2: Four month old SM-Bmal1-/- mice are protected from DOCA-salt induced
aortic aneurysm.
(A) Quantification of abdominal and thoracic aortic outer diameter in control and SMBmal1-/- mice after 3 weeks of DOCA plus salt (B) Incidence of AAA,TAA and aortic
rupture after DOCA plus salt administration (3 weeks). Two-way ANOVA followed by
Bonferroni’s post-hoc analysis was used for statistics in A. Chi Square was used for
comparing AA incidence in B. *: P<0.05, **P<0.01, NS: No significance.

57

A

B

WT

KO

Figure 3: Representative pictures of aortas
Representative pictures of aortas with connected hearts and kidneys from 4 month old
(A) WT and (B) KO mice after 3 weeks of DOCA plus salt
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Maximal intralunimal diameter
of abdominal aorta (mm)
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Incidence (%)

***
80
70
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20
10
0

68.7%
(11/16)
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31.2%
(5/16)
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(0/16)
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(0/16)

TAA

NS
12.5%
(2/16)

0%
(0/16)

Rupture

Figure 4: Eight month old SM-Bmal1-/- mice are protected from DOCA- salt induced
aortic aneurysm
(A) Quantification of inner abdominal aortic diameter by ultrasound in control and SM-Bmal1-/mice prior to and after DOCA- salt (B) Quantification of abdominal and thoracic aortic outer
diameter in control and SM-Bmal1-/- mice after 3 weeks of DOCA-salt (C) Incidence of TAA,
AAA and aortic rupture after DOCA plus salt administration (3 weeks). Two-way ANOVA
followed by Bonferroni’s post-hoc analysis was used for statistics in A and B. Chi Square was
used for comparing AA incidence in C. *: P<0.05, ***P<0.001, NS: No significance.
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WT

A

B

KO

Figure 5: Representative pictures of aortas
Representative pictures of aortas with connected hearts and kidneys from 8 month old
(A) WT and (B) KO mice after 3 weeks of DOCA plus salt
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3.2. Deletion of Bmal1 in vascular smooth muscle cells has no effect on plasma
sodium, mineralocorticoid receptor mRNA, and blood pressure.
Since DOCA plus salt model of aortic aneurysm was shown to be dependent on high salt
intake and to work through the mineralocorticoid receptor, we first investigated whether
Bmal1 deletion in smooth muscle cell prevents plasma sodium increase in response to
DOCA plus salt. We measured plasma sodium before and after DOCA plus salt
administration in control and SM-Bmal1-/- mice. The plasma sodium concentration was
similar in control and SM-Bmal1-/- mice after DOCA plus salt treatment (Fig 6). We also
measured plasma potassium and found similar decrease in plasma potassium in both
control (P<0.05) and SM-Bmal1-/- mice (Fig.7; P<0.01). These results suggest that
Bmal1 deletion from smooth muscle cells does not affect sodium retention or potassium
excretion. Therefore, this is not a mechanism to account for the protection observed in
SM-Bmal1-/- mice.

Second, we investigated the possibility that deletion of Bmal1 in

smooth muscle cells may decrease mineralocorticoid receptor (MR) expression in the
aorta since DOCA plus salt model of AAA is dependent on MR227 . We therefore looked
at both Bmal1 and MR mRNA expression in different regions of the aorta including the
arch, descending, suprarenal, and infrarenal aorta in wild type mice ZT5, ZT11, ZT17
and ZT23 (Fig.8). There was no significant difference in Bmal1 and MR mRNA
expression among the different regions. Even in the suprarenal aorta, where AAA occurs
in mice, Bmal1 and MR mRNA was unchanged. Bmal1 and MR mRNA had a trend
towards a time-dependent variation in their mRNA expression, and, in particular, there
was an inverse temporal correlation between Bmal1 and MR mRNA expression,
indicating that Bmal1 may negatively regulate MR expression. This hypothesis was
investigated by looking at aortic MR mRNA expression in control and SM-Bmal1-/- mice
before and after 7 days of DOCA and salt treatment at ZT17 (Fig.9). DOCA and salt
suppressed MR mRNA expression in the aortic arch (P<0.05) and descending aorta of
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control mice (P<0.001).

A trend for downregulation of MR mRNA was found in

suprarenal and infrarenal aorta. Deletion of smooth muscle Bmal1 had little effect on MR
mRNA expression in the aorta before and after DOCA-salt treatment except for the
descending aorta where deletion of smooth muscle Bmal1 significantly decreased MR
mRNA expression (Fig.9; P<0.01).
As DOCA plus salt administration increases blood pressure and hypertensive patients
have high prevalence of aortic aneurysms230, 231 , we examined blood pressure in control
and SM-Bmal1-/- mice by the tail cuff method to investigate whether the protective effects
of Bmal1 deletion were associated with inhibition of DOCA plus salt induced increases in
blood pressure. First, 4-month-old SM-Bmal1-/- mice had lower blood pressure than
control mice (Fig.10A; P<0.001), consistent with our previous telemetry results.
Interestingly, there was no difference in basal blood pressure between 8-month-old SMBmal1-/- mice and control mice (Fig 10B). Second, perhaps more important, both SMBmal1-/- and control mice , regardless of their ages, increased their blood pressure to a
similar extent in response to DOCA or Aldo plus salt, suggesting that deletion of Bmal1
in smooth muscle has little effect on DOCA or Aldo plus salt-induced hypertension.
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Plasma sodium (mM)
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***
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Figure 6: Deletion of Bmal1 from smooth muscle cells does not affect plasma
sodium level
Sodium content in plasma from control and SM-Bmal1-/- mice at basal and after
21 days of DOCA plus salt treatment. Two-way ANOVA was followed by
Bonferroni’s post-hoc analysis**P<0.01,***P<0.001, NS: No Significance
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Plasma potassium (mM)
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Figure 7: Deletion of Bmal1 from smooth muscle cells does not affect
plasma potassium level
Potassium content in plasma from control and SM-Bmal1-/- mice at basal and
after 21 days of DOCA plus salt treatment. Two-way ANOVA was followed by
Bonferroni’s post-hoc analysis*P<0.05,**P<0.01, NS: No Significance
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Figure 8: Deletion of Bmal1 in smooth muscle has little effect on basal and DOCAsalt-induced MR expression in suprarenal aorta
Aortas were isolated at ZT5, 11, 17, and 23 from ten-week-old C57BL/6J mice (A
through D) Aortas were then cut into arch, thoracic, suprarenal, and infernal aorta.
Relative expressions of MR and Bmal1 mRNA were normalized to 36B4 mRNA
expression. Two-way ANOVA followed by Bonferroni’s post-hoc analysis was used for
statistics in (A through D; N=4).
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Figure 9: Deletion of Bmal1 in smooth muscle has little effect on basal and DOCAsalt-induced MR expression in suprarenal aorta
Aortas were isolated at ZT5 from ten-week-old SM-Bmal1-/- and WT littermates
administered with DOCA-salt for 7 days (A through D). Aortas were then cut into arch,
thoracic, suprarenal, and infernal aorta. Relative expressions of MR mRNA were
normalized to 36B4 mRNA expression. One-way ANOVA followed by Newman-Keuls’
post-hoc analysis was used for statistics in (A through D; N=3 to 4). *P<0.05; **P<0.01;
***P<0.001. NS: not statistically significant.
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Figure 10: Bmal1 deletion does not affect DOCA plus salt induced hypertension
(A) Systolic blood pressure from 4 months old control and SM-Bmal1-/- mice before and
after 21days after DOCA plus Salt treatment (B) Systolic blood pressure from 8 months
old control and SM-Bmal1-/- mice before and after 21 days of DOCA plus Salt treatment .
Two-way ANOVA was used by Bonferroni’s post-hoc correction.**P<0.01,
***P<0.001,NS: No significance
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3.3. Deletion of Bmal1 from smooth muscles cells prevents MMP activation
triggered by DOCA plus salt administration and elastin degradation
One hallmark of aortic aneurysm is elastin degradation which leads to aortic dilation and
subsequently to aortic rupture. We therefore investigated whether Bmal1 deletion eased
DOCA plus salt induced Verhoeff's Van Gieson (EVG) elastin staining. DOCA-salt
induced elastin degradation (Fig 11; P<0.001), and deletion of BMAL1 in smooth muscle
effectively prevented mice from DOCA-salt induced elastin degradation (Fig 11).
Matrix Metalloproteinases (MMPs), in particular MMP2 and MMP9, have been
demonstrated to play a major role in elastin degradation in aortic aneurysms232 .
Therefore, we investigated the effect of deletion of BMAL1 in smooth muscle on DOCA
plus salt-induced MMP activation. We used in situ zymography to measure MMP activity
in abdominal aortic cryosections from SM-Bmal1-/- and control mice administered with
DOCA and salt for 7 days (Fig.12). In the absence of DOCA and salt, little MMP activity
was detected in aorta from both SM-Bmal1-/- mice and controls. In the presence of
DOCA and salt, however, a large MMP activity was readily detected in aorta from control
mice, but not in SM-Bmal1-/- mice (Fig.12), suggesting that deletion of Bmal1 in smooth
muscle prevents mice from DOCA-salt-induced elastin degradation through inhibiting
MMP. We also used in situ zymography to measure MMP activity in paraffin-embedded
abdominal aortas from mice administered DOCA and salt for 21 days. A similar dramatic
protective effect of deletion of Bmal1 in smooth muscle on DOCA-salt-induced MMP
activation was also observed in paraffin-embedded aortas (Fig. 13). It should be pointed
out that using in situ zymography to detect MMP activity in fixed, paraffin-embedded
tissue has been well described229 . However, the detected MMP activity in paraffinembedded aortic section was only found in aortic thrombosis area, which is different
from what we reported in aortic cryosections where MMP could be readily detected in
the media of smooth muscle layer227 , probably reflecting that less MMP activity was
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preserved in paraffin-embedded tissue229. Regardless of these differences, it is clear that
both data indicate a critical role of smooth muscle BMAL1 in DOCA-salt-induced MMP
activation.

69

A
Basal
b

a

e

f

B

g

h

***

20

Elastin Breaks/Area

c

DOCA-salt
d

***

15
10
5
0
WT

KO

Basal

WT

KO

DOCA + Salt

Figure 11: Bmal1 deletion from smooth muscle cells prevents DOCA plus salt
induced elastin degradation
(A) Elastin integrity in control and SM-Bmal1-/- mice after 21 days of DOCA plus salt
administration. (B): Quantification of elastin breaks per surface area, Two-way ANOVA
followed by Bonferroni’s post-hoc analysis. ***P<0.001 .Scale bar:
at lower
magnification: 500μm, higher magnification 100μm
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Figure 12: Bmal1 deletion from smooth muscle cells prevents DOCA plus salt
induced gelatinases activation in the aorta
In situ zymography of cryosections of abdominal aorta from SM-Bmal1-/- mice and WT
littermates administered with DOCA-salt for 7 days. Scale bar: 100μm.
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Figure 13: Deletion of Bmal1 in smooth muscle protects mice from DOCA-saltinduced MMP activation
In situ zymography (e through h and m through p) and phase contrast microscopy (a
though d and I through l) of abdominal aortic cross-sections from SM-Bmal1-/- mice (I
through p) and WT littermates (a through h) with (c, d, g, h, k, l, o, and p) or without
DOCA-salt administration (a, b, e, f, i, j, m, and n). Scale bar: at lower magnification:
500μm, higher magnification: 100μm.
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3.4. Deletion of Bmal1 in smooth muscle selectively increases TIMP4 expression
in abdominal aorta
The protective effect of deletion of Bmal1 in smooth muscle may be attributable to
inhibiting/downregulating MMP2/MMP9 and/or to activating/upregulating tissue TIMPs.
To investigate which mechanism(s) is (are) operating in SM-Bmal1-/- mice, we
determined aortic MMP2 and MMP9 activities in SM-Bmal1-/- and control administered
DOCA and salt for 7 days by gel zymography, a simple but sensitive method to detecting
MMP activity under a condition at which MMPs are dissociated from bound TIMPs233.
Consistent with the results of in situ zymography, a significant or a trend towards
increase in proMMP2, MMP2, proMMP9, and MMP9 activities was detected in control
mice treated with DOCA-salt (Fig. 14A through E). Surprisingly, in sharp contrast to the
result of in situ zymography, deletion of BMAL1 in smooth muscle had little effect on
DOCA-salt-induced proMMP2, MMP2, proMMP9, and MMP9 activities. Moreover, a
significant or a trend towards increase in basal proMMP2, MMP2, proMMP9, and MMP9
activities was found in SM-Bmal1-/- mice relative to that in control mice (Fig. 14A through
E). Since in gel zymography is to detect MMP activity under a condition that all MMPs,
including proMMPs, are activated by SDS, the activity of MMPs detected by in gel
zymography actually is proportional to the level of MMPs protein in samples regardless
they are active or inactive234 . In contrast, in situ zymography is only to detect active
MMPs. Thus, these results suggest that the activity of MMPs, but not the level of MMPs,
is suppressed by the deletion of BMAL1 in smooth muscle. We then investigated the
possibility that the overall inhibition of MMP activity detected by in situ zymography is
attributable to enhanced expression of tissue inhibitors of MMPs (TIMPs). TIMPs are
specific inhibitors of MMPs that control the local activities of MMPs in tissues151, 235. Four
TIMPs (TIMP1, TIMP2, TIMP3, and TIMP4) have been identified and characterized so
far in mammals, and all four TIMPs can inhibit active forms of all MMPs with distinct
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affinity and potency156,

236

. Five different approaches were taken to rigorously test

whether and/or which TIMP(s) in aorta is affected by deletion of Bmal1 in smooth muscle
and/or by DOCA or Aldo plus salt in vivo and ex vivo.
First, we determined mRNA expression of all four TIMPs in aorta in SM-Bmal1-/- and
control mice administered with DOCA and salt for 7 days. All four TIMP transcripts were
found in mouse aorta but among the four TIMPs, Timp4 was the most abundant (Figure
15). The order of relative abundance for the four TIMPs in mouse aorta were TIMP4 >
TIMP3 >TIMP2 >TIMP1. The basal level of TIMP4 was 508-, 427-, and 311-fold higher
than TIMP1, TIMP2, and TIMP3 in control mouse aorta, respectively. Moreover, among
four TIMPs, TIMP4 was selectively upregulated in mouse aorta from SM-Bmal1-/- mice.
There was a trend towards increased TIMP4 mRNA expression in the aorta from WT
mice but it did not reach statistical significance. Interestingly, a significant increase in
TIMP4 mRNA expression was found in aorta from SM-Bmal1-/- mice after DOCA plus
salt treatment. (Fig. 15; P<0.01). The level of TIMP4 was 1,014-, 2,035-, and 559-fold
higher than the levels of TIMP1, TIMP2, and TIMP3 in aorta in SM-Bmal1-/- mice after
DOCA-salt administration, suggesting that TIMP4 may play a major role in inhibiting
DOCA-salt-induced MMP activation. While little changes were found in TIMP1 and
TIMP2 mRNA expression in response to deletion of Bmal1 in smooth muscle and/or
DOCA-salt, a significant increase in TIMP3 mRNA was found in both SM-Bmal1-/- mice
and WT littermates in response to DOCA-salt treatment. However, deletion of Bmal1 in
smooth muscle downregulated TIMP3 mRNA expression before and after DOCA-salt
administration, suggesting that TIMP3 unlikely accounts for the protective effect of
deletion of BMAL1 in smooth muscle on DOCA-salt-induced AAA.
Second, we determined the mRNA expression of all four TIMPs in an aortic organ
culture in the presence of Aldo (10 nM) and high salt (additional 10 mM NaCl) to
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investigate whether DOCA and salt directly or indirectly act on the aorta. The mRNA
expression pattern of TIMP1, TIMP2, TIMP3, and TIMP4 in response to Aldo and salt
observed in ex vivo organ culture (Fig. 16) was similar to that found in vivo although the
extent of increases in TIMP4 mRNA expression were somewhere different. These data
not only verified that deletion of Bmal1 in smooth muscle selectively upregulated TIMP4
mRNA expression in aorta, but demonstrated that Aldo and salt was able to directly act
on aorta ex vivo. Third, we determined TIMP4 mRNA expression in aorta from SMBmal1-/- mice and WT littermates administered with DOCA-salt for 21 days (Fig.17).
Again, TIMP4 was found to be significantly upregulated by deletion of Bmal1 in smooth
muscle (P<0.01) and could be further elevated by DOCA-salt in SM-Bmal1-/- mice
(P<0.05), but not in WT littermates (P<0.001). (Fig.17). Interestingly, the level of TIMP4
increase induced by DOCA-salt was higher at 21 days than at 7 days (182% increase at
7 days vs. 85% increase at 7 days), indicating that DOCA-salt-induced TIMP4
upregulation in SM-Bmal1-/- mice is time-dependent.
Fourth, we determined TIMP4 protein expression in aorta by ELISA in SM-Bmal1-/- mice
and WT littermates administered with DOCA-salt for 7 days to investigate whether
TIMP4 mRNA upregulation leads to its protein upregulation. Quantitative data showed
that deletion of Bmal1 in smooth muscle increased TIMP4 protein expression (Fig. 18;
P<0.001). However, TIMP4 protein was not further increased in aorta by DOCA and salt,
which is different from its mRNA upregulation.
Finally, we determined TIMP4 protein expression by immunohistochemistry in aorta from
SM-Bmal1-/- mice and WT littermates administered with DOCA and salt for 21 days to
investigate the localization of TIMP4 in abdominal aorta. TIMP4 protein was dramatically
upregulated in the media smooth muscle layer of the aorta in SM-Bmal1-/- mice before
and after DOCA-salt administration (Fig. 19). There was no obvious increase in TIMP4
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immunostaining in aorta from WT mice after DOCA-salt treatment, which agrees with
quantitative data by real-time PCR and ELISA.
Taken together, these data indicate that selective upregulation of TIMP4 by deletion of
Bmal1 in smooth muscle may be responsible for its protective effect on DOCA or Aldo
plus salt-induced MMP activation, elastin degradation, and AAA formation.
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Figure 14: Lack of suppression on the MMP2/9 activities by Bmal1 deletion from
smooth muscle cells
(A); Representative gel zymography from the medium in which aortas from control and
SM-Bmal1-/- were incubated after 7 days of DOCA plus salt (B): Pro-MMP2 quantification
from gel zymography(n=4) (C): Active MMP2 quantification from gel zymography (n=4)
(D): Pro-MMP9 quantification from gel zymography (n=4) (E): Active MMP9
quantification from gel zymography . Two-way ANOVA followed by Bonferroni’s post-hoc
analysis **P<0.01, NS: No Significance
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Figure 15: Deletion of Bmal1 in smooth muscle selectively upregulates TIMP4
mRNA expression in aorta
mRNA expressions of TIMP1,TIMP2, TIMP3, and TIMP4 in aortas from SM-Bmal1-/mice and WT littermates at basal condition and after administered with DOCA-salt for 7
days. One-way ANOVA followed by Newman-Keuls’ post-hoc analysis was used for
statistics (N=4-6) *P<0.05, **P<0.01, ***P<0.001. NS: not statistically significant.
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Figure 16: Deletion of Bmal1 in smooth muscle selectively upregulates TIMP4
mRNA expression in aorta.
mRNA expressions of TIMP1, TIMP2, TIMP3, and TIMP4 in aortic organ culture (N=3-4).
Aortas were isolated from SM-Bmal1-/- mice and WT littermates and then incubated with
Aldo (10 nM) and high salt (10 mM increase) medium for 24 h. One-way ANOVA followed
by Newman-Keuls’ post-hoc analysis was used for statistics (N=4) *P<0.05, **P<0.01,
NS, not statistically significant
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Figure 17: Deletion of Bmal1 in smooth muscle upregulates TIMP4
mRNA expression in aorta
TIMP4 mRNA expression in aortas from SM-Bmal1-/- mice and WT littermates
before and after DOCA-salt for 21 days One-way ANOVA followed by
Newman-Keuls’ post-hoc analysis was used for statistics (N=4) *P<0.05,
**P<0.01, ***P<0.001
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Figure 18: Deletion of Bmal1 in smooth muscle upregulates TIMP4 protein
expression in aorta
TIMP4 protein expression was determined by ELISA in aortas from SM-Bmal1-/mice and WT littermates before and after DOCA-salt for 7 days. One-way
ANOVA followed by Newman-Keuls’ post-hoc analysis was used for statistics
(N=4) ***P<0.001. NS: not statistically significant
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Figure 19: Deletion of Bmal1 in smooth muscle upregulates TIMP4 protein
expression in aorta
Representative immunostaining of TIMP4 in paraffin-embedded suprarenal aortic crosssections in SM-Bmal1-/- mice and WT littermates before and after DOCA-salt for 21 days.
Scale bar: at lower magnification (a, c, e, and g): 500 μm, higher magnification (b, d, f,
and h): 100μm.
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3.5. Bmal1 is upregulated in aorta by DOCA and salt.
It is clear that smooth muscle Bmal1 is critically involved in DOCA plus salt-induced
MMP activation, elastin degradation, and AAA formation, which probably involves
TIMP4. However it is unclear how smooth muscle Bmal1 is regulated by DOCA plus salt.
To address this important mechanistic issue, we first investigated whether smooth
muscle Bmal1 mRNA responds to DOCA-salt. An over 6-fold increase in Bmal1 mRNA
expression was found in the aorta from mice administered with DOCA-salt for 7 days
compared to that in control aorta (Figure 20; P<0.001), suggesting that DOCA-saltinduced Bmal1 mRNA upregulation precedes and accounts for its protein upregulation.
To investigate the mechanism by which Bmal1 is upregulated by DOCA-salt, we
determined Per1, Cry1, and Rev-erbA mRNA expression in aorta of mice administered
with DOCA and salt for 7 days as Bmal1 is negatively regulated by Per1, Cry1, and Reverbα under physiological conditions222. We found that DOCA-salt administration had little
effect on Per1 mRNA (Fig.21), significantly increased Cry1 transcripts (Fig. 22; P<0.01),
but downregulated Rev-erbα transcript (Fig. 23; P<0.001), suggesting that DOCA-salt
upregulates Bmal1 through suppressing Rev-erbα in aortic smooth muscle.
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Figure 20: Bmal1 is upregulated after DOCA plus salt treatment
Bmal1 mRNA expression in aortas from control mice before and after DOCA plus
salt for 7 days (N= 5-6). Student’s t test was used for statistics. ***P<0.001
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Figure 21: Per1 is not affected by DOCA plus salt treatment.
Per1 mRNA expression in aortas from control mice before and after
DOCA plus salt for 7 days (N=5-6). Student’s t test was used for
statistics. NS: not significantly different
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Figure 22: Cry1 mRNA increases with DOCA plus salt treatment
Cry1 mRNA expression in aortas from control mice before and after
DOCA plus salt for 7 days (N=5-6). P<0.01 Student’s t test was used
for statistics.
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Figure 23: DOCA plus salt treatment negatively affect Rev-erbα mRNA
expression
Rev-erbα mRNA expression in aortas from control mice before and after DOCA
plus salt for 7 days (N=5-6). Student’s t test was used for statistics. P<0.001
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3.6. Identification of TIMP4 as a new target of Bmal1 in aorta.
To identify the molecular mechanism by which deletion of Bmal1 in smooth muscle
upregulates TIMP4 mRNA and protein, we tested the possibility that Bmal1 may directly
bind to TIMP4 gene promoter and suppressed its transcription.
First, to determine whether Bmal1, as a transcriptional factor, directly binds TIMP4
promoter, we analyzed the mouse TIMP4 promoter DNA sequence and identified
several canonical E-boxes (CANNTG, where N can be any nucleotide) that Bmal1 can
potentially bind to (Fig. 24). To determine whether Bmal1 binds to these putative Eboxes, we performed chromatin immunoprecipitation (ChIP) assays in aortas from WT
mice. The results showed that Bmal1 bound to the TIMP4 promoter at E-box 2 through
E-box 7 except for E-box 5 (Fig. 25).
Second, to investigate whether the binding of Bmal1 to the TIMP4 promoter regulates its
activity, we cloned a 2-kb mouse TIMP4 promoter, inserted it into a luciferase reporter
vector (pGl3-TIMP4p-luc), and transfected the pGl3-TIMP4P-luc vector into aortic
vascular smooth muscle cells isolated from SM-Bmal1-/- and WT littermate mice. In WT
cells, the TIMP4 promoter exhibited a 6-fold increase in luciferase activity over the pGL3
luciferase vector (Fig. 26 A). In contrast, when transfected into in Bmal1-deficient cells,
the TIMP4 promoter activity was further increased by 9-fold over that in WT cells
(Fig.26B), suggesting that TIMP4 transcription is suppressed by Bmal1 in WT cells. The
effective deletion of Bmal1 was verified by quantification of its mRNA (Fig. 27).
Third, to investigate whether the observed Bmal1-mediated TIMP4 transcriptional
suppression translates to its mRNA suppression, we determined TIMP4 mRNA
expression in WT and Bmal1-deficient cells and found that TIMP4 mRNA exhibited a 27fold increase over that in WT cells (Fig. 28;P<0.05), suggesting that Bmal1 suppresses
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TIMP4 promoter activity and mRNA expression in cultured vascular smooth muscle
cells.
Fourth, to investigate whether Rev-erbA, a negative regulator of Bmal1222 , is involved in
upregulation of TIMP4 by deletion of Bmal1 in smooth muscle in response to DOCA-salt,
we determined Rev-erbα mRNA expressions in aorta from SM-Bmal1-/- mice and WT
littermates administered with DOCA-salt for 7 days. Deletion of Bmal1 in smooth muscle
or administration of mice with DOCA-salt alone had similar potency in suppressing Reverbα transcript (Fig.29; P<0.001), but combination of both of them further suppressed
Rev-erbα transcript (Fig.29; P<0.05), suggesting that their inhibitory mechanisms are
different. These results also suggest a possibility that Rev-erbα suppresses TIMP4
under physiological conditions and downregulation of Rev-erbα by deletion of Bmal1 in
smooth muscle or administration of mice with DOCA-salt abolishes this suppression and
results in TIMP4 upregulation. To test whether Rev-erbα binds to the TIMP4 promoter to
suppress its transcription, we searched Rev-erbα response elements (AGGTCA) in the
2-kb mouse TIMP4 promoter but we were unable to find one (Z. Guo and M. Gong,
unpublished observation), suggesting that it is unlikely that Rev-erbα directly binds to the
TIMP4 promoter to suppress its transcription.
Finally, we were intrigued by the fact that Bmal1, generally thought of as a transcriptional
activator, suppress TIMP4 transcription. To address this important issue, we determined
Cry1 mRNA expression in aorta from in SM-Bmal1-/- mice and WT littermates
administered with DOCA and salt for 7 days as it has been shown Cry1 can interact with
Bmal1 to switch Bmal1 from a transcriptional activator to a transcriptional repressor237. If
this is involved in Bmal1 to regulation of TIMP4, the Cry1 transcript should be
upregulated. The results supported this possibility (Fig.30).
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Figure 24: TIMP4 Promoter contains E-boxes
Schematic diagram of 2-kb mouse TIMP4 promoter showing 7 E-boxes and ChIP-PCR
primers. E1-E7: E-box1-7; F (forward)/R (reverse) primers.
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Figure 25: Bmal1 binds to TIMP4 promoter
Representative aortic tissue ChIP PCR showing that Bmal1 binds to TIMP4 promoter at
E-box 2, 3, 4, 6, and 7, but not E-box 5.
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Figure 26: Deletion of Bmal1 increases TIMP4 promoter activity in smooth muscle
cells
(A) TIMP4 promoter activity relative to pGL3-basic vector in WT aortic VSMC. (B) TIMP4
promoter activity in aortic VSMC from SM-Bmal1-/- mice and WT littermates. Student’s t
test was used for statistics in A and B. **P<0.01,***P<0.001
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Figure 27: Bmal1 is deleted in Bmal1 KO VSMC
Bmal1 mRNA expression in aortic VSMC from SM-Bmal1-/- mice and
WT littermates. (N=3) Student’s t test was used for statistics **P<0.01
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Figure 28: TIMP4 expression is increased in aortic VSMC
TIMP4 mRNA expression in aortic VSMC from SM-Bmal1-/- mice and
WT littermates (N=3). Student’s t test was used for statistics *P<0.05
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Figure 29: Deletion of Bmal1 in smooth muscle downregulates Reverbα mRNA expression in aorta
Rev-erbα mRNA expression in aorta from SM-Bmal1-/- mice and WT
littermates before and after DOCA-salt for 7 days. One-way ANOVA
followed by Newman-Keuls’ post-hoc analysis was used for statistics
(N=5-6), *P<0.05,***P<0.001.
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Figure 30: Deletion of Bmal1 in smooth muscle upregulates Cry1
mRNA expression in aorta
Cry1 mRNA expression in aorta from SM-Bmal1-/- mice and WT littermates
before and after DOCA-salt for 7 days One-way ANOVA followed by NewmanKeuls’ post-hoc analysis was used for statistics (N=5-6) , *P<0.05, **P<0.01, NS:
not statistically significant
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3.7. Deletion Bmal1 in vascular smooth muscle cells protects from Angiotensin II
plus salt-induced aortic aneurysm
We have seen that deletion of Bmal1 in smooth muscle showed a dramatic protection
from DOCA plus salt induced aortic aneurysm. Moreover, such protective effect was
associated with prevention of the massive MMP activation and up-regulation of TIMP4.
These results suggest that the up-regulated TIMP4 may inhibit the overall MMP activity
to provide the protection. Since the activation of MMP is believed to be responsible for
the final degradation of ECM and aortic dilation, a key event can be triggered by
divergent up-stream insults. Therefore, we determined whether Bmal1 deletion could
provide a broad protection from aortic aneurysm triggered by divergent insults.
To test this possibility, we used a modified model of ANGII induced aortic aneurysm. We
administered ANGII for 28 days followed by salt for 14 days in SM-Bmal1-/- and littermate
controls. Ultrasound quantification of the intraluminal diameter of the abdominal aorta
showed a modest time-dependent dilation after ANGII alone in control mice, this dilation
further increased with the presence of high salt. As expected, the abdominal aortic
dilation was suppressed in SM-Bmal1-/- (Fig.31 A; P<0.01). The maximal external
diameter was more pronounced in control mice than SM-Bmal1-/- (Fig. 31 B). The
incidence of aortic aneurysm was significantly decrease from 56.2% in control vs 0% in
SM-Bmal1-/-

(P<0.01), and TAAs were decreased from 31.2% in control vs 0% in SM-

Bmal1-/- (P<0.05). No rupture occurred in SM-Bmal1-/- out of 11 mice while 2 rupture
occurred within the control group out of 16 mice (Fig. 31 C). Fig. 32 shows photographs
of a normal aorta from the SM-Bmal1-/- mice and a typical aneurysmal aorta from the
control mice administered with ANGII and high salt.
We had also examined blood pressure increase in those mice which showed that ANGII
alone increases blood pressure in both SM-Bmal1-/-and control mice (Fig. 33; P<0.001).

96

However, after ANGII blood pressure increased but remained lower in SM-Bmal1-/- than
control mice (P<0.01).
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Figure 31: Eight month old SM-Bmal1-/- mice are protected from Angiotensin II
followed by salt induced aortic aneurysm
(A) Quantification of inner abdominal aortic diameter by ultrasound in control and SMBmal1-/- mice prior to and after ANGII- salt (B) Quantification of abdominal and thoracic
aortic outer diameter in control and SM-Bmal1-/- mice after 4 weeks of ANGII followed by
2 weeks salt (C) Incidence of TAA, AAA and aortic rupture after 4 weeks of ANGII
followed by 2 weeks salt administration (6 weeks). Two-way ANOVA followed by
Bonferroni’s post-hoc analysis was used for statistics in A and B. Chi Square was used
for comparing AA incidence in D. *: P<0.05, **P<0.01, NS: No significance.
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A
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Figure 32: Representative pictures of aortas from 8 month old mice after ANGII
Representative pictures of aortas with connected hearts from 8 month old (A) WT and
(B) KO mice after 4 weeks of ANGII followed by 2 weeks of salt
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Figure 33: Bmal1 deletion does not affect Angiotensin II induced
hypertension
Systolic blood pressure from 8 months old control and SM-Bmal1-/mice before and after 28 days after ANGII treatment.Two-way ANOVA
was used by Bonferroni’s post-hoc correction **P<0.01, ***P<0.001.
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3.8 SM Bmal1 heterozygous mice are not protected from DOCA plus Salt induced
Aortic Aneurysm

We wanted to determine whether both copy of Bmal1 in smooth muscle cells are
required for the protection that we have observed in DOCA plus salt induced model of
aortic aneurysm and ANGII plus salt induced model of aortic aneurysm. To answer this
question, we used 8 month old SM-Bmal1+/- and littermate control mice and administered
DOCA plus salt for 21 days. We found that the control mice had a time dependent
increase in maximal intraluminal diameter, and the SM-Bmal1+/- mice had a modest but
significant decrease (Fig. 34 A; P<0.05). The incidence of abdominal aortic aneurysm
formation went from 50% in control mice to 35.7% in SM-Bmal1+/- mice and in TAAs from
41.6% to 35.7%. One rupture occurred in the SM-Bmal1+/- out of 14 and 2 occurred in
control mice (Fig. 34 B). Although, there is a decrease in maximal intraluminal diameter
of the abdominal aorta and a decrease in aortic aneurysm incidence, overall the
decrease in incidence did not reach significance. This suggests that to see a complete
protection from aortic aneurysm, both copies of Bmal1 have to be deleted in smooth
muscle cells. Fig. 35 shows photographs of aortas from the SM-Bmal1+/- and the control
mice administered with DOCA and high salt. We had also measured blood pressure
which shows no change between SM-Bmal1+/- and the control mice before and after
DOCA plus salt (Fig.36).
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Figure 34: Eight month old SM-Bmal1+/- mice are not protected from DOCA- salt
induced aortic aneurysm
(A) Quantification of inner abdominal aortic diameter by ultrasound in control and SMBmal1+/- mice prior to and after DOCA- salt (B) Incidence of TAA, AAA and aortic rupture
after DOCA plus salt administration (3 weeks). Two-way ANOVA followed by
Bonferroni’s post-hoc analysis was used for statistics in A. Chi Square was used for
comparing AA incidence in B. *: P<0.05, NS: No significance.
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Figure 35: Representative pictures of aortas
Representative pictures of aortas with connected hearts and kidneys
from 8 month old (A) WT and (B) SM-Bmal1+/- mice after 3 weeks of
DOCA plus salt
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Figure 36: One Copy of Bmal1 does not affect mineralocorticoid receptor
agonists induced hypertension
Systolic blood pressure from 8 months old control and SM-Bmal1+/- mice before
and after 21days after DOCA plus Salt treatment. Two-way ANOVA was used by
Bonferroni’s post-hoc correction NS: No significance.
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CHAPTER 4
Discussion
4.1. Overview of the study
AAA is a complex multifactorial disease of unknown etiology. AAA is characterized by
different features including MMP activation, elastin degradation, inflammation, oxidative
stress and smooth muscle cell atrophy. Smooth muscle cells have been considered the
epicenter of AAA formation since they modulate early and late events that lead to aortic
rupture238. Since AAA is so complex and the causative effects are unknown, a direct
therapeutic target has proven challenging to develop. Therefore, there is an urgent need
to better understand the disease and find a therapeutic target. Disruption of the Bmal1
gene is associated with vascular diseases as well as metabolic diseases. However, the
actual role that Bmal1 plays in vascular smooth muscles cells has not been established.
We hypothesized that Bmal1 plays a critical role in AAA formation. We deleted Bmal1 in
vascular smooth muscle cells and found that this protects from AAA formation. The
protection is independent of blood pressure increase.

Therefore, we tested other

molecular mechanisms and found that Bmal1 deletion increases TIMP4 expression in
the vasculature which in turn inhibits MMP2 and MMP9 activities. This inhibition prevents
elastin degradation and aortic dilation, protecting against AAA formation. Thus, this
study identifies Bmal1 as new key player in the pathogenesis of AAA.
4.2. Bmal1 is ubiquitously expressed and has a specific function in the
vasculature
The embryonic global Bmal1 knockout, or conventional, Bmal1 knockout mice have a
shorter lifespan and display signs of early aging and age-related pathologies239. They
also have impaired glucose tolerance, reduced insulin secretion, and are susceptible to
diabetes.

They

have

abnormal

bone
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calcification,

eye

pathologies

and

neurodegeneration240-242. Finally, they display phenotype such as infertility and increased
sensitivity to chemotherapy243, 244. Mechanistically, these phenotypes may be caused by
an increase in oxidative stress and MMP activities.
Since Bmal1 is expressed in different parts of the brain and in peripheral tissues
including smooth muscle cells. Researchers have recently been investigating the role
that Bmal1 plays in vascular diseases. Anea et al. have shown that when the carotid
arteries of Bmal1 Knockout mice were ligated, Bmal1 knockout mice had higher
remodeling than control mice211. Other studies have demonstrated that deletion of Bmal1
in mice causes increased vascular superoxide and endothelial NO synthase
uncoupling220. However, these studies involved the germline global deletion of Bmal1,
making it challenging to determine whether these pathologies resulted from Bmal1
function in the vasculature or a systemic disruption from multiple systems. One effective
approach to distinguish the tissue specific role of Bmal1 vs. the systemic function of
Bmal1 would be tissue specific deletion of Bmal1.
In order to investigate the role that Bmal1 might play in specific tissues, investigators
have generated tissue specific Bmal1 knockout mice. Thus far, there have been no
reports of early aging and shorter lifespan in these tissue specific knockouts. However,
there have been multiple reports that suggest Bmal1 regulates metabolism. Deletion of
Bmal1 in skeletal muscle does not lead to loss of locomotor activities as seen in the
conventional Bmal1 knockout mice. Relative to WT mice, the skeletal muscle specific
Bmal1knockout mice have a normal lifespan, a slight increase in bodyweight, altered
muscle glucose metabolism, and muscle insulin resistance245. Mice lacking Bmal1 in the
liver have normal local insulin sensitivity , normal total body fat content, and
hypoglycemia246. Mice with Bmal1 deletion in the pancreas have normal bodyweight,
fasting hyperglycemia, severe glucose intolerance and diabetes247. Mice with a deletion
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of Bmal1 in adipose tissue have normal local insulin sensitivity but develop obesity248.
Mice lacking Bmal1 in the heart have a cardiomyopathy and have early mortality249.
When smooth muscle cell specific Bmal1 knockout mice were used to determine the role
of Bmal1 in blood pressure regulation, Bmal1 in smooth muscle cells was shown to be
required for normal amplitude and time-of-day variations of vascular smooth muscle
contraction and normal blood pressure circadian rhythms221. Thus, these studies suggest
that the use of tissue specific Bmal1 abrogates systemic effects of Bmal1 deletion from a
prenatal stage. Therefore, in order to determine the role of vascular Bmal1 in AAA
pathogenesis, we selected to use smooth muscle specific Bmal1 knockout mice.
4.3. Smooth muscle cells initiate events leading to AAA formation and rupture
In order to avoid the systemic effects of the global Bmal1 knockout mice, we used
smooth muscle cell specific Bmal1 knockout mice. Smooth muscle cells are the major
cell type in the aorta250, and they modulate early events of AAA formation238. Ailawadi et
al. had demonstrated that SM22 alpha and smooth muscle alpha actin, which are
smooth muscle cell markers, are decreased in the formation of AAA using the elastase
model. They had also observed an increase in MMP2 and MMP9 in smooth muscle238.
Smooth muscle is a source of elastolytic activities, which are thought to be the initial
event in AAA formation. Isolated smooth muscle cells from AAA synthesize higher levels
of MMP2 and MMP9 than non-aneurysmal tissues132,

251-253

. Furthermore, they also

secrete inhibitors of MMPs. Secretion of TIMP1 from smooth muscle cells has been well
described24. This increase in metalloproteases by smooth muscle cells and the
subsequent degradation of the elastin are part of the initial event of AAA formation. This
is followed by an infiltration of inflammatory cells in the vasculature. Lee et al. have
reported an increase in other metalloproteinases such as MMP1 and MMP3 after
smooth muscle cell interaction with monocytes254 . This increase has been attributed to
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an IL-1 dependent mechanism254. Increase in inflammatory cytokines such as IL-1 and
IL-6 further intensifies the expression of MMPs and their inhibitors255. Reactive Oxygen
Species (ROS) in smooth muscle cells also play an important role in the AAA formation.
ROS also lead to smooth muscle cell apoptosis. Li et al. had demonstrated that H2O2 is
the major species that leads to a depletion of smooth muscle cell population in the
aorta256. The depletion of smooth muscle cell leads to the expansion and rupture of the
aorta. Together, these observations suggest that smooth muscle cells are key players in
AAA formation and rupture.

Using smooth muscle specific Bmal1 knockout, we

demonstrated that deletion of Bmal1 in smooth muscle cells abolishes AAA formation
and subsequently we have identified smooth muscle Bmal1 as a new player in the
formation of AAA.
4.4. Gelatinases MMP2 and MMP9, and TIMP4 play a role in AAA formation
To gain insight into the protective mechanism from deletion of Bmal1, we focused on
MMPs. The degradation of the elastin layer due to an imbalance between MMPs and
their endogenous inhibitors is one of the hallmarks of AAA257. Our data showed that
smooth muscle specific Bmal1 knockout mice are protected from DOCA plus salt
induced elastin degradation. Two well characterized elastin degrading enzymes in AAA
formation are MMP2 and MMP9258. Both MMPs are first secreted as inactive
proenzymes and are then activated by other MMPs259. MMP2 is predominantly produced
locally by smooth muscle cells and adventitial fibroblasts, and to a lesser extent from
macrophages, while MMP9 is primarily produced by macrophages260. Longo et al.
investigated the importance of MMP2 and 9 in aortic aneurysm formation using MMP2
Knockout mice and MMP9 knockout mice, and concluded that both MMP2 and MMP9
were necessary for aortic aneurysm formation59, since inhibition of either MMP2 or
MMP9 or both resulted from complete protection from AAA formation. In accordance
108

with these results, our data demonstrated that MMP2 and MMP9 activities are inhibited
in the aorta of smooth muscle cells Bmal1 knockout mice after DOCA plus salt
administration. This suggests that MMP inhibition is part of the mechanism by which
smooth muscle Bmal1 knockout mice are protected from developing AAA. These results
support numerous studies implicating MMP2 and MMP9 as major players in the
formation of AAA and rupture.
Under normal physiological conditions, the activities of MMPs are tightly regulated by
TIMPs. An imbalance between MMPs and TIMPs favoring MMP activation leads to an
increase in vascular remodeling, vascular diseases such as atherosclerosis261, and AAA
formation. This indicates that TIMPs play an important role in aortic aneurysm formation.
Among the four TIMPs that have been identified, TIMPs 1, 2, and 3 play an important
role in AAA formation. Three polymorphisms in TIMP1 have identified; two of these have
been associated with AAA in patients173. Mice lacking TIMP1 develop larger aneurysms
after elastase infusion than control mice66, and local overexpression of TIMP1 inhibits
elastin degradation, aortic aneurysm formation and rupture in rats. On the other hand,
deletion of TIMP2 attenuated aortic aneurysm formation in mice61 while an
overexpression in TIMP2 inhibited aortic aneurysm formation in rats174. Whereas the role
of TIMP1 is clearly understood as inhibitory for MMPs, the role of TIMP2 remains
ambiguous, probably due to the double influence of TIMP2 on MMP2: an increase in
TIMP2 activates proMMP2 and an overexpression of TIMP2 inhibits MMP2 activation175.
Global deletion of TIMP3 in mice causes an increase in aortic aneurysm formation176.
Our data by in situ zymography clearly showed that MMP activities were inhibited in
SMC-Bmal1-/- mice. We had also seen that TIMP4 was the only TIMP upregulated and
TIMP4 is a strong inhibitor of gelatinases

179

. Thus, TIMP4 likely inhibited MMP2/9

activity in vivo. Future studies with TIMP4 knockout mice will be necessary to definitively
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conclude this. The role of TIMP4 in aortic aneurysm formation has not previously been
reported. This study implicates TIMP4 in the protective mechanism of Bmal1deletion in
smooth muscle cells against AA formation on the basis of the following observations. In
the absence of Bmal1, TIMP4 mRNA and protein increases significantly. TIMP4 is the
most abundant among all the TIMPs in the aorta. In response to DOCA or Aldo plus salt,
TIMP1, 2, and 4 mRNA do not respond (i.e., increase) to the treatment. DOCA plus salt
increases TIMP3 mRNA in vivo. These results are similar with data found in dilated aorta
from patients with aortic aneurysm, where the TIMP3 mRNA was the only TIMPs
upregulated among the four TIMPs262, which suggests a compensatory mechanism.
TIMP4 is a new target for Bmal1 in the aorta through binding several E-boxes. Within the
promoter, TIMP4 does not contain a TATA box, but contains an initiator sequence and
relatively few identifiable transcription–factor-binding consensus motifs263,

264

and we

have identified several E-boxes within the promoter. Promoter assays have shown
increased TIMP4 promoter activity in the absence of Bmal1 in smooth muscle cells,
while the presence of Bmal1 attenuated the promoter activity.
4.5. Hypertension is not a risk factor for AAA formation and does not account for
the protection in SMC-Bmal1 Knockout mice
Decreasing blood pressure is unlikely a mechanism underlying the protective effect from
aortic aneurysm in SMC-Bmal1-/- mice. Hypertension was widely described as a risk
factor for AAA formation. However, recent evidence argues this concept. Using the
ANGII model to induce aortic aneurysm, Manning et. al had demonstrated that
doxycycline, a broad spectrum inhibitor of MMPs, had significantly reduced AAA
formation in LDL receptor knockout mice. However, doxycycline had no effect on ANGII
induced hypertension74. Although vitamin E75 and 17β estradiol70 had attenuated AAA
formation in APOE knockout mice using ANGII, no difference was observed in systolic
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blood pressure with vs. without treatment. DOCA plus salt, a model that has widely been
used to induce hypertension, has recently been described as a model that also induced
AAA227. In this model, losartan and enalapril decreased the systolic blood pressure after
DOCA plus salt treatment, but did not alter the rate of aortic aneurysm formation227.
More studies using genetically deleted genes have supported the evidence that
hypertension is not a risk factor for AAA formation. A genetic deletion of uPA265,
osteopontin266 and BLT267 in ApoE knockout mice had decrease AAA formation after
ANGII infusion, but had no effect on systolic blood pressure.268 Further investigation in
castrated ApoE male mice showed a decrease in AAA formation and no change in
systolic blood pressure268, 269. The Tsukuba hypertensive mice, which develop AAA after
high salt intake, did not differ in systolic blood pressure after high salt intake when
compare to the control57. Thus in a variety of different experimental settings AAA
formation occurs independently of increased blood pressure.
Nevertheless, we determined whether SMC-Bmal1 KO mice had altered blood pressure.
Our data showed that the protection we observe in smooth muscle knockout mice is
independent of blood pressure increase. Although the knockout mice have a lower basal
systolic blood pressure, the blood pressure in response to DOCA plus salt increases in
both control and the knockout mice with the same amplitude. Therefore, AAA formation
is independent of blood pressure increase and the protection seen in smooth muscle
Bmal1 Knockout mice is independent of blood pressure. Indeed, other investigators have
demonstrated that lower blood pressure after DOCA plus salt treatment does not protect
from AAA formation227.
4.6. Abdominal aortic aneurysm formation is not a circadian related disease
Our data identified TIMP4, a gene not related to clock genes, as a new target for Bmal1.
As a transcription activator, Bmal1 not only regulates the expression of clock genes, but
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also regulates the expression of many other genes. Many of the Bmal1 targeted genes
are related to metabolism. Through a genome-wide profiling, Hatanaka et al. have found
that Bmal1 regulated 10 to 15% of all transcripts including clock genes in different
tissues270. Therefore, disruption of Bmal1 may result in disruption of regulated genes,
leading to different disorders circadian or non-circadian related. Bmal1 has been
associated with hypertension271. Diseases such as hypertension or stroke are
considered to be circadian related diseases, because they disturb a 24 hour pattern and
they also have circadian pattern of symptoms. In AAA, the rupture has diurnal variations.
Most patients with ruptured AAA are admitted in early morning with a peak between 8:00
am and 10:00 am, the lowest admittance of patients have been between 2:00 pm and
4:00 pm272. This pattern had mirrored the circadian rhythm of systolic blood pressure273.
Here, we see that disruption of Bmal1 in the vasculature leads to protective effects from
AAA formation. Since Bmal1 is a core clock gene and regulate other clock genes,
diseases associated with Bmal1 could be interpreted as circadian or clock related
disease. Although, the rupture of AAA is circadian in pattern, AAA formation will not be
considered circadian. In AAA formation, the integrity and structure of the aortic wall is
destroyed and is independent of the variation of time. Therefore, AAA formation would
not be considered as a circadian related disease.
4.7. Limitations of the study and future directions
By using smooth muscle cell specific Bmal1 knockout mice, we have avoided the
systemic effect of the prenatal global deletion of Bmal1 in mice. However, the effect of
deleting Bmal1 at the embryonic stage in smooth muscle still remains. Yang et al. have
developed an inducible global Bmal1 knockout mouse to overcome the effect of deletion
of Bmal1 at the embryonic stage. Although, these mice had a complete loss of
rhythmicity in all tissues, they displayed phenotypes that were different from the
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conventional Bmal1 knockout mice. These mice had a normal lifespan, normal blood
glucose and, though they display some sign of early aging such as ocular abnormalities,
they retain fertility, normal body weight, and normal organ size274. These mice had
additional phenotypes that were opposite to the conventional Bmal1 knockout mice in
hair growth and atherogenesis. The inducible Bmal1 knockout mice had increased
growing follicles across all ages and a consistent expression of Ccnd1 and Mik67 genes,
hair growth promoting genes, in the skin274. The difference in phenotypes between the
inducible Bmal1 mice and the conventional Bmal1 mice as was suggested by Yang et al.
may be attributed to an important role that Bmal1might play during the embryonic stage.
Therefore, deletion of Bmal1 during that stage might be the contributing factor to early
aging and subsequent phenotypes. Hence, a future goal would be the use of an
inducible smooth muscle cell specific Bmal1 to investigate AAA formation.
Our data suggest that the absence of Bmal1 in the vasculature is beneficial since Bmal1
protects from AAA and decreases blood pressure.

However, targeting smooth muscle

cells Bmal1 for therapeutic treatment would be damaging because blood pressure loses
its rhythmicity in such animals221. Therefore, the best target may be TIMP4, which our
data demonstrated to be downstream of Bmal1 and may contribute to protection from
AAA. However, the present study fails to conclusively demonstrate a direct involvement
of TIMP4 in aortic aneurysm formation. The other TIMPs 1, 2 and 3 have been
demonstrated to play a role in aortic aneurysm formation, but the role of TIMP4 has yet
to be adequately explored. The best approach to determine the role that TIMP4 plays in
aortic aneurysm formation would be to use TIMP4 knockout mice, TIMP4 transgenic
mice, or to locally overexpress TIMP4 on the aorta and administer DOCA plus salt to
induce aortic aneurysm. TIMP4 knockout mice have been generated and have been
shown to be susceptible to myocardial infraction followed by a right ventricular wall
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rupture and death129. However, these mice have not yet been available for purchase to
the public. Our findings predict that using TIMP4 knockout mice to induce aortic
aneurysm, would lead to an increase in rate of AAA formation after DOCA plus salt or
Angiotensin II plus salt; while using TIMP4 transgenic mice or local overexpression of
TIMP4 would lead to a protection from AAA formation.
We were unable to precisely demonstrate the mechanism by which Bmal1 regulates
TIMP4 expression. Multiple lines of evidence show that Bmal1 acts as a transcription
factor when bound to an E-box. While we have shown that Bmal1 binds to TIMP4
promoter and the absence of Bmal1 increases TIMP4 promoter activity, we have also
shown that deletion of Bmal1selectively increases TIMP4 expression (Fig. 15-19). These
data suggest that Bmal1 acts as a break on theTIMP4 promoter. Determining whether or
not Bmal1 directly regulates TIMP4 expression has been challenging. One suggested
mechanism of regulation was that Rev-erb could act as a repressor. Bmal1 regulates
Rev-erb by binding to E-box at the promoter region, and Rev-erb in turn inhibits Bmal1
by binding to a response element. Therefore, we explored the possibility that Rev-erb in
the presence of Bmal1 would bind to TIMP4 promoter and repress its expression.
However, TIMP4 does not contain a rev-erb response element in its promoter region.
Another mechanism envisions the possibility that the interaction between Bmal1 and
Cry1, which has been shown to act as a repressor237, could repress TIMP4 expression.
Although, our results have demonstrated an upregulation of Cry1 in the absence of
Bmal1, which is consistent with the study from Kondratov et al, more work is needed to
confirm that it is the interaction between Bmal1 and Cry1 represses TIMP4 expression.
It will also be important to explore the mechanism for the increase in Bmal1mRNA
expression after DOCA plus salt treatment. Aldosterone and angiotensin II have been
shown to induce Bmal1 circadian rhythmicity in H9c2 cardiomyoblasts and vascular
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smooth muscle cells respectively214,
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. Our Data have shown that Bmal1 expression

increases in response to DOCA plus salt (Fig. 20), whether this increase is an actual
increase, or a shift in rhythmic expression, has not been determined in this study. Bmal1
expression fluctuates during the day and the expression pattern could have shifted after
DOCA plus salt treatment. Therefore, to address this question the expression of Bmal1
in the aorta should be examined prior to and after DOCA plus salt/ aldosterone and salt
or ANGII plus salt administration in mice at different times of the day. The data could be
further tested by looking at Bmal1 expression in VSMC at different times of the day with
or without aldosterone and high salt or ANGII plus salt treatment.
One last issue that has not been explored in this study would be to determine whether
deletion of Bmal1 in smooth muscle protects from aortic aneurysm across different
models of aortic aneurysm. We have shown that smooth muscle cell specific Bmal1
knockout mice are protected from DOCA plus salt induced AAA and from angiotensin II
plus salt. The DOCA plus salt model has been used for decades to study hypertension,
but it has only been recently shown that it can also induce aortic aneurysm227. ANGII
plus salt has only been used in our study. Models of aortic aneurysm using angiotensin II
have used apoE knockout mice or LDR knockout mice to induced AAA. Therefore, the
use of other chemically induced models such as calcium chloride and elastase will
determine how broad the protection extends. Both models depend upon different
mechanisms but an increase in MMP2 and MMP9 is seen in these models. In this study,
we have concluded that the protection is partially due to an increase in TIMP4
expression. Since TIMP4 inhibits both MMP2 and MMP9, we hypothesize that smooth
muscle cell Bmal1 knockout mice will be protected or show an attenuation from aortic
aneurysm induced by calcium chloride or elastase infusion.
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4.8. Conclusions
In this study, we have identified Bmal1 has a key player in the formation of AAA and
identified a potential mechanism. We have therefore demonstrated that: 1) Vascular
smooth muscle cell deletion of Bmal1 protects from aortic aneurysm formation. 2)
Vascular smooth muscle cell deletion of Bmal1 does not affect MR expression before
and after DOCA plus salt in the aorta except for the descending aorta. 3) Vascular
smooth muscle cell deletion of Bmal1 does not affect plasma sodium. We then explored
the mechanism and found the following: 1) Vascular smooth muscle cell deletion of
Bmal1 prevents DOCA plus salt induced MMP2/MMP9 increase in vivo. 2) Vascular
smooth muscle cell deletion of Bmal1 selectively increases TIMP4 expression. 3) Bmal1
binds to TIMP4 promoter and Bmal1 presence represses TIMP4 expression. 4) The
protection seen in this model is independent of blood pressure increase.
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